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ABSTRACT

USE OF PROCALCITONIN AS A BIOMARKER OF BACTERIAL INFECTION IN
ACUTE LIVER FAILURE AND ACUTE LIVER INJURY
By Jody Anne Balko, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2012
Advisor: William J. Korzun, Ph.D., Associate Professor, Department of Clinical
Laboratory Sciences
Infections in patients with acute liver failure (ALF) and acute liver injury (ALI)
are a frequent occurrence. Because ALF and ALI patients share many of the same
clinical features as patients with severe sepsis and septic shock, identifying an infection
based upon clinical manifestations is extremely difficult. Bacterial culture and sensitivity
reports require 24 to 72 hours to be finalized after the need for a culture is suspected and
obtained. During this time period, ALF and ALI patients are either not receiving required
antibiotic therapy, receiving antibiotic therapy that is not required or not appropriate for
the infecting bacterial pathogen, or receiving the correct antibiotic prophylaxis.
Receiving an antibiotic that is not needed or inappropriate adds another level of
complexity to the ALF and ALI patients because antibiotics may exacerbate liver
dysfunction.

The purpose of this study was to determine the utility of serum procalcitonin
concentrations (SPCTC) as a biomarker of bacterial infections in patients with acute liver
failure (ALF) and acute liver injury (ALI). This three part study measured SPCTC
retrospectively on samples from ALF and ALI patients who were prospectively enrolled
in the United States Acute Liver Failure Study Group (USALFSG) ALF and ALI studies.
In the first part of the study, subjects were categorized according to how many SIRS
continuum components they had and whether there was a documented infection. In the
second part, serial samples on subjects who developed infections were identified. And, in
the third part, serial samples on subjects diagnosed with infection on day one of the study
and categorized based upon transplant free survival (TFS) or death and/or liver transplant
(DoT) were identified.
Procalcitonin was not found to be useful in identifying infection in the ALF and
ALI patient populations. A cut-off for indication of infection was calculated to be 1.62
ng/mL using receiver operator curve (ROC) analysis. Despite the fact that there was an
overall increase in SPCTC as the severity of illness increased in patients with a
documented infection, there were confounding variables including antibiotic use, missing
data, and small sample size that may have contributed to the poor sensitivity and
specificity (0.643 and 0.620 respectively) calculated as part of the ROC analysis.
SPCTC values appeared to be increased in subject with acetaminophen (APAP)
toxicity and may have affected the cut-off, sensitivity, and specificity results. Increased
SPCTC values were seen in APAP subjects who did not have a documented infection. It

is unknown at this time if the SPCTC were increase due to liver damage, an undiagnosed
infection, or as a result of increase cytokine production due to the APAP toxicity.
Serial PCT concentrations in patients who achieved TFS showed a greater
decrease over time than those of patients who died or received a liver transplant,
however, the TFS group contained a large portion of APAP subjects. Further prospective
studies are needed to determine the extent of interference with SPCTC in patients with
APAP toxicity and to better define the PCT concentration cut-off between infection and
no infection in the ALF and ALI populations.

CHAPTER 1: INTRODUCTION

Infections are a frequent occurrence in patients diagnosed with acute liver failure
(ALF) and acute liver injury (ALI). Overall mortality in patients with ALF has been
estimated at 30 – 40%. Approximately 44% of ALF patients are listed for liver
transplantation with 12 – 25% of all ALF patients receiving a liver transplant (Bower,
Johns, Margolis, Williams, & Bell, 2007; Lee, Squires, Nyberg, Doo, & Hoofnagle,
2008). Bacterial infections are reported to occur in 40% - 90% of ALF patients (Rolando
et al., 2000; Vaquero et al., 2003). The mortality rate due to bacterial infection (or
suspected bacterial infection) in the general population increases from approximately
10% in patients with systemic inflammatory response syndrome (SIRS), to approximately
50% in patients with septic shock (Brun-Buisson, 2000; Rangel-Frausto et al., 1995).
ALF has many of the same characteristics of septic shock and the presence of SIRS in
ALF is associated with a poor prognosis (Antoniades, Berry, Wendon, & Vergani, 2008).
Studies have shown a link between bacterial infection and increasing mortality in ALF
(Rolando et al., 1990; Rolando et al., 2000). Another study has indicated a relationship
between bacterial infection and the progression to stage III-IV hepatic encephalopathy
(HE) and a decrease in spontaneous (survival without liver transplant) survival (Vaquero
et al., 2003). However, there are no studies specifically looking at bacterial infection in
the ALF population related to the SIRS spectrum and to clinical outcome. Currently,
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methods to detect and identify bacterial infections and antibiotic sensitivities require at
least 24 to 72 hours to produce results. Furthermore, cultures may be negative even if an
infection is present (Fenollar & Raoult, 2007). Various methods utilizing molecular
techniques have been developed in an effort to speed up and/or improve identification of
infection-causing bacteria. While these techniques may improve the time to result for
organisms that require longer incubation periods (days to weeks) to grow and isolate, the
techniques do not improve the time to result for pathogens requiring shorter incubation
periods (24 – 48 hours) to grow and isolate (Sabet, Subramaniam, Navaratnam, &
Sekaran, 2006; Stefani, 2009).
A biomarker that can provide an immediate determination that a bacterial
infection is present and can give an indication of severity would provide a major
improvement in the ability to treat ALF and ALI patients who have a bacterial infection.
Procalcitonin (PCT) is a biomarker of inflammatory response that requires one to two
hours to obtain a result and tends to increase with the severity of the infection. Studies
indicate that elevated PCT values are associated with most types of bacterial infections
(Brunkhorst, Wegscheider, Forycki, & Brunkhorst, 2000; P. E. Charles et al., 2008;
Christ-Crain, M., Jaccard-Stolz, D., Bingisser, R., Gencay, M. M., Huber, P. R., Tamm,
M., et al. (2004). PCT has a half-life of 25 to 30 hours suggesting that a short-term rise
or fall in the serum PCT concentration (SPCTC) could be indicative of a change in a
patient’s infection status. The PCT molecule is stable in serum or plasma samples for up
to 24 hours at 4oC, making accurate measurement of PCT feasible. SPCTC is a potential
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candidate for measurement in the clinical laboratory to monitor patients for bacterial
infection and sepsis (Jin & Khan, 2010).
In studies in patients with sepsis, pneumonia, and other types of infections, PCT
has been shown to be a good indicator of bacterial infection and a useful tool in guiding
antimicrobial therapy (Muller, Christ-Crain, & Schuetz, 2007). In patients with liver
disease, PCT has been examined in patients who have had liver transplant and in patients
hospitalized with chronic liver disease (cirrhosis), but there are no studies of patients with
ALF or ALI (Elefsiniotis et al., 2006).
Purpose of This Study
The purpose of the study was to retrospectively examine the levels of PCT in
patients with ALF and ALI with and without evidence of bacterial infection to determine
the usefulness of procalcitonin as a biomarker of infection in ALF and ALI patients. The
U.S. Acute Liver Failure Study Group (USALFSG) maintains ALF and ALI databases to
prospectively collect clinical information about ALF and ALI that is used to conduct
clinical trials aimed at improving treatment for ALF and ALI patients. The USALFSG
was established in 1998 with pilot funding from the FDA and is currently supported by
the National Institute of Health (NIH).
The ALF/ALI databases include 632 documented cases of infection (248 blood,
304 urine, 49 catheter, 21 wound, 17 ascites, 238 tracheal aspirates, and 48 others (source
not specified)) from a total of 1829 patients. This study examined the utility of SPCTC as
an indicator of bacterial infection in ALF/ALI patients.
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Specific Aims
There were three main aims for this study:
Specific Aim 1: To determine if there are differences in SPCTCs between noninfected ALF and ALI patients and non-infected chronic liver disease patients,
between infected and non-infected ALF and ALI patients, and between ALF and
ALI patients with different severities of infection and those published for the
general population.
This was determined by measuring SPCTCs from sera that were collected from ALF and
ALI patients who were prospectively enrolled in the ALF and ALI studies with a
documented history of infection, ALF and ALI patients without an infection, and chronic
liver disease patients without an infection. Chronic liver disease subjects were
prospectively enrolled in one of two investigator-initiated databases maintained at the
University of Texas Southwestern Medical Center (UTSW): The Liver Disease Database
and the Nucleic Acid, Serum, and Tissue Repository for the Study of Liver Diseases
(NSTLD). The results were analyzed according to etiology of liver disease, the presence
or absence of infection, and the severity infection based upon clinical signs and
symptoms.
Specific Aim 2: Determine the utility of SPCTC as a screening biomarker for
infection in ALF and ALI patients
SPCTC was measured in sera collected on the three days prior to diagnosis of infection
and on the day an infection was identified (i.e., the day a positive culture was obtained),
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to determine whether PCT will allow an earlier indication of infection than clinical
symptoms or culture findings.
Specific Aim 3: Determine if SPCTC in ALF and ALI patients with bacterial
infection on Day 1 of the ALF or ALI study is associated with patient outcomes.
SPCTCs were measured in serial samples from ALF and ALI patients with known
infections, to determine whether there are differences in the SPCTCs between patients
with unfavorable outcomes (death or transplant) and those with favorable outcomes
(transplant free survival).
Summary
Infection in ALF and ALI patients is a serious complication that may be difficult
to detect because ALF and ALI subjects have clinical manifestations that are similar to
septic shock. In addition, reports of bacterial cultures require 24 – 72 hours before they
are available to the clinician.
SPCTC has been proposed as a biomarker of infection/sepsis that can reduce the
time needed to detect bacterial infections and thereby allow earlier initiation of
antimicrobial therapy. Multiple studies show that SPCTC has good sensitivity for
detection of bacterial infection and indicate that SPCTC can decrease the length of
antibiotic treatment. While there are multiple studies relating SPCTC to the detection of
infection, there have only been a few studies on patients with chronic liver disease and
none on ALF or ALI patient populations. In this study, the efficiency of SPCTC to detect
infection and to predict outcomes in ALF and ALI patients was investigated.

CHAPTER 2: LITERATURE REVIEW

The following chapter will present background information relevant to
procalcitonin, acute liver failure and injury, the pathophysiology of infection and sepsis,
and the need to identify infections quickly. First, a description of procalcitonin, its
origin, and its use as a biomarker for detecting and monitoring treatment of infection and
sepsis will be presented. Next, information describing acute liver failure and acute liver
injury and the need for a rapid determination of infection or sepsis in these populations
will be presented. Next, information describing the pathophysiology of infection and
sepsis will be presented. An overview of current methods for the diagnosis of bacterial
infection and the strengths and weaknesses of these methods will be presented. Finally,
background relating to the rationale for using procalcitonin to detect and monitor
treatment of infection and sepsis in patients with acute liver failure or injury will be
discussed.
Liver Structure and Physiology
The liver is composed of single cell thick sheets of hepatocytes arrayed around
the central vein forming a hexagon. The hepatocyte sheets are separated by sinusoidal
spaces that contain the Kupffer cells, endothelial cells, and stellate cells. The sinusoidal
spaces allow blood flow from the hepatic artery and portal vein to the central vein. The
canaliculi between the hepatocytes drain into ductules that empty into the bile duct. The
6
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hepatic artery, portal vein, and bile duct are located in the portal tracts located in the
corners of the hexagons (Khalili, Liao, & Nquyen, 2010).
Hepatocytes compose approximately 80% of the total number of liver cells in an
adult liver. Hepatocytes are the “metabolic factories” of the liver and are involved in
carbohydrate, fat, and protein metabolism as well as the production of bile. An important
feature of the hepatocyte is its ability to regenerate if a portion of the liver is lost or
removed (Barrett, 2006).
Kupffer cells, which develop from the macrophage lineage, line the sinusoidal
endothelium on the blood stream side of these cells and have highly active phagocytic
properties, scavenging colonic bacteria that enter the bloodstream from the intestines by
way of the portal vein. Activation of Kupffer cells by host or foreign antibodies may
result in the production of cytokines and other inflammatory mediators that contribute to
liver injury (Barrett, 2006).
Endothelial cells lining the hepatic sinusoids have a unique structure that allows
macromolecules (such as albumin bound with various substances) produced by the
hepatocytes, to move out of the cells into the blood stream while preventing formed
elements in the blood (e.g., red blood cells, white blood cells, and platelets) from entering
the hepatocytes. The structure also allows remnant macromolecules back into the
hepatocyte. The structure of the sinusoidal endothelial cells is contractile and is
controlled in part by various hormones and neurotransmitters. If the sinusoidal
endothelial cells are damaged, passage of these macromolecules into the hepatocyte can
be disrupted (Barrett, 2006).
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Stellate cells store a variety of lipids, the most predominant of which is vitamin A.
Stellate cells play a major role in liver injury by responding to inflammatory cytokines.
When activated, the stellate cells lose their stores of vitamin A and up-regulate the
production of extra-cellular matrix materials, such as collagen, which is deposited in the
space between the hepatocytes and the sinusoidal endothelial cells, causing a disruption
of hepatic function and leading to cirrhosis (Barrett, 2006).
Liver disease (acute or chronic) may result from impairment or death of one or
any combination of the liver cell types. Liver function tests are the most commonly used
method to assess liver injury. Liver function tests include measurement of serum
aspartate aminotransferase (AST), alanine aminotransferase (ALT), gammaglutamyltransferase (GGT), alkaline phosphatase (ALP), albumin, total and direct
bilirubin, and plasma prothrombin time (PT) [converted to international normalized ratio
(INR)] and ammonia. Liver function tests may be abnormal due to death of the
hepatocytes (AST, ALT), failure of the liver to secrete bile called cholestasis (bilirubin,
GGT, ALP), or disruption of metabolic and synthetic functions (PT/INR, ammonia,
albumin). The degree to which the individual liver function tests are affected depends
upon which cellular structures or functions are damaged and the amount of damage that
occurs (Khalili et al., 2010; Merriman & Peters, 2003; Moseley, 2003; Barrett, 2006).
As the degree of damage to the liver increases and ammonia levels rise, hepatic
encephalopathy (HE) may occur. While the pathophysiology of HE is not completely
understood, what is known is that the disruption of the urea cycle in the liver leads to an
increase in ammonia and other toxins. In ALF, massive astrocyte swelling and cerebral
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edema due to an increase in glutamine production characterize HE and increased
vasodilation possibly due to systemic release of gut-derived endotoxins, proinflammatory cytokines, and stimulation of nitric oxide synthase. As blood ammonia
levels increase, cerebral ammonia levels also rise due to an impaired blood brain barrier
(BBB) as the result of vasodilation. Increasing cerebral ammonia levels lead to the
increased production of glutamine from glutamate by glutamine synthetase in the
astrocyte, which is the only cell in the brain that contains this enzyme. Increased
glutamine production results in astrocyte swelling. As the astrocytes swell, more
ammonia is allowed to cross the BBB increasing the glutamine levels further and
eventually resulting in cerebral edema and ultimately death by cerebral herniation
(Barrett, 2006; Mendler, Donovan, & Blei, 2003).
Acute Liver Failure and Acute Liver Injury
Acute liver failure is characterized by severe liver cell dysfunction that occurs
suddenly in patients with no known underlying liver disease. It is also known as
fulminant hepatitis or fulminant hepatic failure. Although ALF was first described as a
specific disease in the early 1950s, it was not until 1970 that it was defined as fulminant
hepatic failure including HE. HE is cerebral dysfunction without structural abnormalities
in the presence of liver disease. The extent of the dysfunction is graded (West Haven
criteria grades) I – IV where grade I represents minimal dysfunction (trivial lack of
awareness or shortened attention span) and grade IV represents coma (unresponsive to
stimuli) (Ferenci et al., 2002; Trey & Davidson, 1970). The definition of ALF has been
revised to include certain chronic liver diseases that can present as ALF but in retrospect,
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have been present but unrecognized, specifically Wilson’s Disease and hepatitis B. These
two diseases are unique in having very rapid onset of acute liver injury in the presence of
low grade chronic form of the disease (Khashab, Tector, & Kwo, 2007; Lee, 2003; Trey
& Davidson, 1970).
In the United States (US), ALF is estimated to affect between 2000 and 2800
people per year (Bower et al., 2007; Khashab et al., 2007; Ostapowicz et al., 2002;
Schiodt et al., 1999). Patients admitted to the hospital with ALF typically demonstrate
increased levels of liver enzymes in serum, the abnormal coagulation (coagulopathy
indicated by prothrombin time (PT) greater than 15 seconds or international normalized
ratio (INR) greater than 1.5), plus hepatic encephalopathy and without evidence of
cirrhosis (Lee & Seremba, 2008; Ostapowicz et al., 2002; Schiodt et al., 1999).
There are multiple etiologies of ALF. Previously, viral hepatitis (hepatitis A, B,
and C) was the most common cause of ALF in the US (Schiodt et al., 1999). Currently,
acetaminophen overdose constitutes the largest single cause of ALF accounting for 46%
of all cases. Other etiologies include drugs (11%), hepatitis B virus (7%), hepatitis A
virus (3%), autoimmune hepatitis (5%), ischemia (4%), and Wilson’s disease (2%).
Diseases or events, other than those listed previously, cause 7% of ALF cases and 14% of
cases are from indeterminate causes (Lee & Seremba, 2008).
The etiology of ALF varies worldwide. Western countries (including Australia)
document the majority of their ALF cases as being due to acetaminophen (paracetamol)
toxicity. The United Kingdom reports a high prevalence of suicidal overdoses using
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acetaminophen in the 1990s, accounting for 73% of ALF cases (Ostapowicz et al., 2002).
That has decreased in part due to legislation to restrict sales of acetaminophen to a level
of 57% (W. Bernal, Auzinger, Dhawan, & Wendon, 2010). In Asia and other developing
countries, viral hepatitis (hepatitis A, B, and E) remains the leading cause of ALF. There
is no vaccine for hepatitis E and vaccines for hepatitis A and B are less available in these
countries. Hepatitis A and E are mainly transmitted by fecal-oral transmission routes and
are closely associated with poor hygiene and sanitation. Hepatitis E is now the most
common cause of ALF in India, Pakistan, China, and Southeast Asia (W. Bernal et al.,
2010). The unavailability of many of the therapeutic drugs known to cause ALF in these
countries is another reason why viral hepatitis is the leading cause of ALF in developing
countries (W. Bernal & Wendon, 2000; Boeker, 2001; Ostapowicz et al., 2002; Polson &
Lee, 2007).
Common therapeutic (both prescription and non-prescription) drugs that have
been documented as causing ALF include acetaminophen (as previously noted), antituberculosis, antiepileptic, and antibiotic pharmaceuticals. Antibiotics that have
frequently been cited as causing ALF include isoniazide, sulfa-related compounds,
quinolones, amoxicillin, and flucloxacillin. Telithromycin (Ketek), a recently released
antibiotic, underwent a subsequent review by the US Food and Drug Administration
(FDA) advisory panel, which resulted in severely limited future use and a “black box
warning”. A “black box warning” is a warning mandated by the FDA to appear on the
full prescribing information of a prescription medication. Such a warning must be printed
inside a box with a black outline at the top of the information sheet used by doctors and
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pharmacists. A modified version of the same warning will appear on the patient
information sheet. The restrictions resulted from numerous reports of ALF with short
onset (as few as two days from initial use to symptoms of ALF), presence of abdominal
pain, fever, and ascites (Lee & Seremba, 2008; Mindikoglu, Magder, & Regev, 2009).
While viral hepatitis and drug induced liver injury account for the majority of
ALF worldwide, other etiologies are known. Autoimmune hepatitis (AIH) is an immunemediated disease in which human leukocyte antigen (HLA) class II antigens are present
on the surface of the hepatocyte and are the apparent target of the immune attack by the
body’s immune system. The immune response is complex and may involve T-cell
activation, adhesion between immune synapses, cytokine production, and T-cell receptor
configuration (Heathcote, 2003). Ischemia can result from a reduction of the blood flow
to the liver due to systemic circulatory collapse or occlusion of the hepatic vein. Systemic
circulatory collapse may result from loss of intravascular volume (hypovolemia) due to
blood loss or other fluid loss due to massive diarrhea, congestive heart failure, or septic
shock. Occlusion of the hepatic artery (Budd-Chiari Syndrome) may result from
thrombus, fibrous obliteration, or tumor invasion (DeLeve, 2003). Metabolic anomalies
result in the disruption of pathways that are important in the synthesis or transport of
proteins in the liver, of which Wilson’s disease (progressive accumulation of copper in
hepatocytes) is the most common form seen in the US. Acute liver disease during
pregnancy may also result in acute liver failure (Sokol, 2003). While there are three main
forms of acute liver disease in pregnancy, acute fatty liver of pregnancy (AFLP) is the
form most commonly seen in ALF. The cause of AFLP is unknown. Mild symptoms of

13
liver disease generally begin near 35 weeks gestation and may quickly progress to ALF
and death (of mother and baby) if delivery is not initiated (Zimmermann & Christman,
2003).
Spontaneous recovery from ALF occurs in less than 50% of patients.
Approximately 40% are placed on liver transplant waiting lists, but only 25% of the
overall ALF population, receive a liver graft. Overall, 30% of patients diagnosed with
ALF die within 21 days of the onset of illness (Bower et al., 2007; Lee & Seremba,
2008). Causes of death include cerebral edema, multi-organ failure, sepsis, cardiac
arrhythmia or arrest, and respiratory failure (Ostapowicz et al., 2002).
Acute liver injury (ALI) is similar to ALF in that it is characterized by sudden
severe liver cell dysfunction in patients with acute illness of less than 26 weeks duration
(less than 2 weeks for acetaminophen etiology) but with no evidence of HE at the time of
hospital admission. HE is diagnosed by neuropsychiatric evaluations focusing on mental
and motor status (Ferenci et al., 2002). If HE develops, the patient’s diagnosis changes to
ALF. At the time of hospital admission, patients with ALI, as defined by the USALFSG,
present with increased liver enzymes, and coagulopathy (prothrombin time (PT) greater
than 20 seconds or international normalized ratio (INR) greater than 2.0) but do not
demonstrate any encephalopathy.
When ALF is described in gastroenterology textbooks (Mendler et al., 2003),
there is no distinction between ALF and ALI, as HE is graded as 0, 1, 2, 3, or 4. All
information describing ALF and patient demographics above are based upon the ALF
definition that does not include the ALI patients who have a HE grade of 0. Information
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characterizing the ALI subject population will be presented below, however, for the
purposes of this study ALF and ALI will be distinguished only by their coma grade: ALI
patients have a presenting coma grade of zero and ALF patients and ALI patients who
develop HE have coma grades of 1 – 4. Throughout the rest of this discussion, unless a
distinction between ALF and ALI is necessary, ALF will be used to refer to both ALF
and ALI subjects in this study.
The etiologies of ALI are the same as those of ALF. While there are no figures
available that document the number of ALI cases in the US, the USALFSG has estimates
of the number of the various etiologies and the outcomes of ALI. Of the 163 ALI cases
in the USALFSG database collected prior to October 1, 2010, 23% went on to develop
HE and were transferred to the ALF database. Ninety one percent of the ALI cases went
on to attain transplant free survival while 7% required a liver transplant and 2% died. As
with ALF, acetaminophen poisoning accounts for the largest percentage of ALI cases
(60%). Autoimmune hepatitis (10%) and drug-induced liver injury (9%) account for the
next two largest numbers of cases. Other etiologies include hepatitis B virus (5%),
hepatitis A virus (1%), mushroom poisoning (2%), shock (<1%), hepatitis E virus (<1%),
and acute fatty liver of pregnancy (<1%). Diseases or events other than those listed
caused 2.5% of ALI cases and cases from indeterminate causes account for 8% of the
cases (United States Acute Liver Failure Study Group, 2011).
Bacterial Infection and Sepsis
Infection is a pathologic process that is initiated when normally sterile tissue or
fluid or a body cavity is invaded by pathogenic or potentially pathogenic microorganisms
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(Levy et al., 2003). Common types of infections that are diagnosed and treated by
physicians include wound infections, urinary tract infections, upper respiratory tract
infections, pneumonia, and intestinal tract infections. All of these can range in severity
due to the specific organism, the patient’s status (co-existing conditions, age, etc.), and
whether or not treatment is received in a timely fashion.
SIRS, Sepsis, Severe Sepsis, and Septic Shock
The 1992 American College of Chest Physicians (ACCP) and the Society of
Critical Care Medicine (SCCM) Consensus Conference convened to “to provide a
conceptual and practical framework to define the systemic inflammatory response to
infection, which is a progressive injurious process that falls under the generalized term
‘sepsis’ and includes sepsis-associated organ dysfunction as well” (Levy et al., 2003).
Prior to this point, the terms sepsis, sepsis syndrome, and septic shock were used
interchangeably when referring to various points on the continuum of the infection
process (from signs and symptoms of infection to septic shock and organ dysfunction).
The definitions for systemic inflammatory response syndrome (SIRS), sepsis, severe
sepsis, and septic shock were developed and later reviewed and revised by the 2001
SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference sponsored
by the SCCM, ACCP, the European Society of Intensive Care Medicine (ESICM), the
American Thoracic Society, and the Surgical Infection Society. The revised terms are
widely used today by physicians to make clinical decisions but are not diagnostic in
nature. The terms only provide a means for identifying which specific criteria that
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patients meet when they are suspected of having a systemic response to infection (Levy et
al., 2003; Nystrom, 1998; Rangel-Frausto, 2005).
The term systemic inflammatory response syndrome (SIRS) was introduced to
describe the activation of the immune response system by localized or generalized
infection, trauma, thermal injury, or sterile inflammatory processes. SIRS can be initiated
by both infectious and non-infectious conditions. Patients with SIRS are defined as
having two or more of the following clinical findings:


Body temperature of >380C or <360C



Heart rate >90 beats per minute



Respiration rate >20 breaths per minute



PCO2 <32 mm Hg (normal approximately 35 – 45 mmHg)



White blood cell (WBC) count >12.0 x 103 cells/mm3 of blood , <4.0 x 103
cells/mm3 of blood, or >10% bands (immature cells)

However, these criteria are too non-specific to be useful in identifying a specific cause
(infectious vs. non-infectious) for the activation of the immune response (Levy et al.,
2003).
Sepsis was defined by the 2001 conference as SIRS in the presence of a
confirmed infection. Infection resulting in sepsis sets off a cascade of inflammatory
processes that lead to activation of the coagulation system. This eventually leads to
alterations in microvascular circulation that result in organ dysfunction. Positive
identification of an infection can be a difficult and lengthy process. Therefore, if one or
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more of the following conditions and SIRS are present, a presumptive diagnosis of sepsis
can be made:


Significant edema or positive fluid balance (fluid intake greater than fluid output
of 20 mL/kg over 24 hrs or more)



Hyperglycemia (plasma glucose >120 mg/dL) in the absence of diabetes



Biomarkers of acute inflammation: plasma C-reactive protein >2 SD above the
normal value or plasma procalcitonin >2 SD above the normal value



Mixed venous oxygen saturation (SVO2) >70% (measured from a pulmonary
artery, with a high value indicative of low oxygen demand resulting from such
causes as hypothermia, anesthesia, pharmacologic paralysis, and sepsis



Cardiac index >3.5 L/min/M2 (normal amount of blood pumped while the body is
“at-rest” by the ventricles per minute relative to body size is 3 L/min/M2)

These criteria are signs of potential early organ failure that may trigger a physician to
think that a patient “looks” septic (Edwards, 1991; Khalili et al., 2010; Levy et al., 2003;
Mohrman & Heller, 2006).
Severe sepsis is defined as sepsis with organ dysfunction. Organ dysfunction,
hypoperfusion, and hypotension variables denoting septic shock include (but are not
limited to):


Arterial hypoxemia (PaO2/fraction of inspired oxygen [FiO2] ratio of <300 torr –
normal values are >400; <300 is indicative of acute lung injury)



Acute oliguria (urine output <0.5 mL/kg/h for at least 2 h)



Creatinine >0.5mg/dL increase above baseline
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Coagulation abnormalities (international normalized ratio >1.5 or activated partial
thromboplastin time >60 sec)



Thrombocytopenia (platelet count <100,000/mm3)



Hyperbilirubinemia (plasma total bilirubin >4 mg/dL or 70 mmol/L)



Hyperlactatemia (>1 mmol/L)



Arterial hypotension (systolic blood pressure <90 mmHg, mean arterial pressure
(MAP) <70 mmHg (calculation based upon systolic and diastolic values; the
average arterial blood pressure during a single cardiac cycle and normally 70 –
110 mmHg), or a systolic blood pressure decrease >40 mmHg from baseline)



Altered mental status

These parameters represent one level of organ dysfunction. The degree of organ
dysfunction may be defined by using the Sequential Organ Failure Assessment (SOFA).
SOFA is a six-organ dysfunction/failure score that measures the function of the lungs,
coagulation, liver, heart, central nervous system, and kidneys. When using the SOFA
system, each organ is graded on a scale of 0 – 4 depending upon the level of the
parameter being assessed. Patients with severe sepsis exhibit a level of organ dysfunction
that corresponds roughly with SOFA level of two for each organ system (Levy et al.,
2003; Mohrman & Heller, 2006; Nystrom, 1998).
Septic shock is a state of acute circulatory failure that is characterized by
hypotension even with adequate resuscitation with fluids and is unexplained by any other
cause. The 2001 Consensus Conference (Levy et al., 2003) defined the level of
hypotension in septic shock using the following levels:
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Systolic arterial pressure < 90 mm Hg



Mean arterial pressure (MAP) <60 mm Hg



A reduction in systolic blood pressure >40 mm Hg from baseline
For physicians who have to identify patients with SIRS, sepsis, severe sepsis, and

septic shock, these definitions still present difficulties since none of the criteria in the
current definitions are specific for infection or sepsis. Physicians still resort to the clinical
impression that “he/she looks septic” then looks for a source of infection by ordering
various cultures and tests to identify a causative agent (Levy et al., 2003).
ALF has many clinical similarities to septic shock leading to the suspicion that
they share pathogenic mechanisms that lead to the progression from SIRS to multiple
organ dysfunction. ALF patients are prone to infection due to loss of the protective
effects of the liver further confusing the picture: “What is ALF without sepsis?” and
“What is sepsis in ALF?”. Studies have shown that the presence of SIRS in ALF is
associated with progression to hepatic encephalopathy and that the hemodynamic profile
in ALF patients is similar to that seen in septic shock. While the systemic inflammatory
profile is well understood in sepsis and septic shock, this is not the case in ALF
(Antoniades et al., 2008; Rolando et al., 2000; Vaquero et al., 2003).
While SIRS and sepsis in ALF have not been well studied to date, ALF patients
do have an increased risk of infection and subsequently developing sepsis and sepsisinduced organ failure (Rolando et al., 2000; Wade et al., 2003; Stravitz, 2008). There is
much confusion between signs and symptoms of ALF and signs and symptoms of sepsis.
The overlap pertains to the fact that the diagnosis of sepsis requires the finding of a
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positive blood culture, which is often delayed or not detected, even in cases where
presumptive evidence of bacterial infection is very strong. It has been estimated that as
many as 80% of ALF patients develop bacterial infections. The most common types of
infections include pneumonia (50%), urosepsis (22%), IV catheter-induced bacteremia
(12%), and spontaneous bacteremia (16%). Infection is associated with progressive
worsening of HE, and is one of the most common causes of multi-organ dysfunction and
death in ALF (Stravitz, 2008; Vaquero et al., 2003).
There are multiple reasons for this susceptibility to infection. Patients with acute
liver failure have immunological defects that include impaired function of the white
blood cells and decreased activity of plasma proteins, including components of the
complement cascade. ALF patients are also subject to an increased use of invasive
procedures that are associated with increased risk of infection. Such procedures include
insertion of intravenous lines, monitors for intracranial pressure and arterial pressure,
urine catheters, and mechanical ventilators. Cerebral edema increases the chance of lung
infection because chest physiotherapy and bronchial suction are contraindicated.
Methods to Identify Bacterial Organisms
Diagnosis of bacterial infection by the microbiology laboratory is a time
consuming multi-step process. The process of identifying an infection begins by choosing
an appropriate specimen, proper collection of the specimen to avoid contamination,
prompt transportation to the laboratory, and providing the laboratory with appropriate
information concerning the specimen and the patient. Once the specimen is in the
laboratory, the historical approach to identifying bacterial pathogens involved inoculating
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the specimen onto appropriate culture medium and incubating the culture specimen for 24
to 48 hours. If bacteria grow, isolated colonies are chosen to subculture for identification
and antibiotic susceptibility testing, requiring an additional 24 hours. The total time
required to identify the offending organism and determine its antimicrobial susceptibility
profile is typically 48 to 72 hours (Levinson, 2010).
In some cases, additional time is required because patients have previously
received antibiotics or the infectious organisms are slow growing. Some organisms will
not grow using standard culture techniques, require special media or other growth
conditions, and some bacteria do not survive the collection and transport process
(Fenollar & Raoult, 2007; Peters, van Agtmael, Danner, Savelkoul, & VandenbrouckeGrauls, 2004; Schrenzel, 2007; Sixou, 2003; Stefani, 2009). Despite these drawbacks,
culture remains the gold standard for the detection of bacteria in patients with infections.
Cultures have the advantage because they can identify both organisms that are suspected
and those that are unsuspected as being the cause for infections (Sixou, 2003).
In the past 10 to 20 years, new methods have been developed to identify bacteria
causing infections. These methods include polymerase chain reaction (PCR),
fluorescence in situ hybridization (FISH), DNA-based microarray, mass spectroscopy,
and immunoassay. FISH and PCR techniques have been shown to decrease the time
required to identify bacteria from blood culture samples (Peters et al., 2004; Stefani,
2009). PCR has been shown in multiple studies to be able to identify bacteria directly
from blood culture bottles (Gebert, Siegel, & Wellinghauser, 2008; Jaffe, Lane, Albury,
& Niemeyer, 2000; Kilic, Muldrew, Tang, & Basustaoglu, 2010; Ruimy et al., 2008;
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Stefani, 2009), from culture swabs (Francois et al., 2003), from cerebral spinal fluid (du
Plessis, Smith, & Klugman, 1998), and from colonies already isolated in culture (du
Plessis et al., 1998; Geha, Uhl, Gustaferro, & Persing, 1994; Georghiou et al., 1995;
Hsueh et al., 1998; Sabet et al., 2006; Sarwari et al., 2004). Mass spectroscopy, while not
commonly used, has been shown to identify bacteria accurately from isolates and clinical
samples (Ho & .Reddy, 2010). Microarray techniques have been used to identify bacteria
both from isolates (Strommenger et al., 2007) and from blood culture bottles (Tissari et
al., 2010). Many of these technologies can identify specific bacterial species and strains
that have known susceptibility patterns. While this does not eliminate the need for
antimicrobial sensitivity studies, it may improve the process of identifying appropriate
antibiotic therapy in some cases (Francois et al., 2003; Ruimy et al., 2008; Stefani, 2009;
Strommenger et al., 2007; Tissari et al., 2010).
All of these methods show promise by decreasing the time required to identify
bacteria from clinical specimens, but major drawbacks. In all cases, you can only “find
what you are looking for” (Sixou, 2003). The probes required for the FISH, PCR, and
microarray techniques are pre-determined. The selected probes will test for multiple
bacterial species and strains but multiple arrays must be used to expand the range of
organisms that can be detected. Mass spectroscopy requires either pure culture isolates or
significant pre-treatment of samples to identify organisms in complex specimens (Ho &
Reddy, 2010). PCR techniques are susceptible to laboratory contamination and
background bacterial DNA from either dead organisms or from organisms that are
present but not responsible for the infection (Stefani, 2009).
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Procalcitonin
Procalcitonin is the precursor form of calcitonin, a hormone whose primary
source is the parafollicular C cells of the thyroid gland. Calcitonin has a hypocalcemic
and hypophosphatemic effect, inhibiting bone resorption, and stimulating the kidney to
excrete phosphorus, calcium, and sodium. Calcitonin can be used as a biomarker of
medullary thyroid cancer (MTC). However, the mechanisms by which calcitonin
produces the above effects in the human body are not known. The removal of the thyroid,
gland such as for treatment of MTC, does not cause a disruption in calcium hemostasis
(Becker, Nylen, White, Muller, & Snider, 2004; Bracq et al., 1993; Carrol, Thomson, &
Hart, 2002; Muller & Becker, 2001).
PCT is one of a group of peptides in the calcitonin super-family of peptides. Other
peptides in the group include calcitonin gene-related peptide I, II (CGRP-I, CGRP-II),
amylin, and andrenomedullin. The PCT peptide has an approximate molecular weight of
14.5 kDa and consists of a sequence of 116 amino acids. Both PCT and CGRP-I are
encoded by the Calc-1 gene located on chromosome 11p15.4 (Christ-Crain & Muller,
2008; Jin & Khan, 2010; Russwurm, Oberhoffer, Zipfelk, & Reinhart, 1999). The peptide
has three regions (Figure 1): the PCT amino terminus, the mature calcitonin segment, and
the carboxyl-terminus called katacalcin (Carrol et al., 2002).

Figure 1: Schematic of Procalcitonin Molecule
Figure was derived from E.D. Carrol et al., (2002) International Journal of Antimicrobial Agents, 20: 1-9.
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In the absence of infection, the production of PCT outside of the neuroendocrine
cells of the thyroid and the lung is suppressed. In the presence of sepsis, all tissues
produce PCT. Because of this dual role, PCT is considered a “homokine”. Homokines
can either act as a hormone as in the normal physiologic state or as a cytokine during
inflammatory processes (Muller & Becker, 2001; "PCT in patients with sepsis", n.d.). To
date no other causes of PCT increase has been determined.
The factors mediating the production of homokines are as yet unknown. It may be
induced either by toxins produced by bacteria or by humoral- or cell-mediated host
response. As with other cytokines, there is little intracellular storage of PCT during
sepsis. While synthesis of PCT is necessary for the production of calcitonin, animal
studies have shown that increased concentrations of PCT may have lethal effects during
sepsis. Administration of PCT to septic hamsters with peritonitis doubled the death rate to
over 90%. Immunoneutralization of PCT by the administration of antiserum in septic
hamster and pig studies led to increased survival of these animals (Muller & Becker,
2001; Nylen et al., 1998; Nystrom, 1998; Whang et al., 1999).
Procalcitonin Testing
Most PCT assays have been developed in cooperation with BRAHMS Diagnostic
GmbH. BRAHMS placed the first PCT assay into use in 1996, with a rapid test following
in 1999. The FDA approved the use of the manual BRAHMS PCT LIA (formerly
LUMItest PCT) in the US in 2005. The BRAHMS PCT LIA, (“Immunoluminometric
assay (ILMA) for the determination of PCT”, 2005) is a dual monoclonal antibody
luminescence immunoassay. The assay uses a coated tube technique in which the anti-
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calcitonin capture antibody is immobilized on the inner surface of the tube and a second
anti-calcitonin antibody is labeled with a luminescent acridine derivative. During the
incubation phases of the procedure, PCT is “sandwiched” between the two calcitonin
antibodies. The amount of PCT in the sample is determined by measuring the
luminescence signal using a luminometer when Basiskit LIA reagents are added to the
tube. The intensity of the luminescence signal (RLUs, relative light units) is directly
proportional to the PCT concentration. The assay takes two to three hours to complete,
requires standards and controls to be analyzed with each run, and is usually performed in
batch mode ("Immunoluminometric assay (ILMA) for the determination of PCT (coated
tube system)", 2005; McGee & Baumann, 2009; Steinbach et al., 2004).
The first automated PCT assay was the BRAHMS KRYPTOR assay. The
KRYPTOR assay received FDA clearance for use in the US in March 2008. This assay
uses Time Resolved Amplified Cryptate Emission (TRACE) technology, with a nonradiative transfer of energy. The PCT molecule is sandwiched between a PCT antibody
tagged with europium cryptate (donor) and a PCT antibody tagged with XL665
(acceptor) forming an immune complex. When a pulsed nitrogen laser at 337 nm excites
the sample, the donor emits a fluorescent signal at 620 nm with an excited state t1/2 in the
milli-second range. The acceptor emits a fluorescent signal at 665 nm with an excited
state half-life (t1/2) in the nano-second range. If the donor and acceptor are bound in an
immune complex, the fluorescent signal of the acceptor is amplified, and its t1/2 is
prolonged to the microsecond range by resonance energy transfer from the donor. The
signal intensity at 665 nm is proportional to the amount of PCT in the sample. The assay
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calibration is good for seven days and results are available in 25 – 40 minutes
("BRAHMS PCT sensitive KRYPTOR", 2008; McGee & Baumann, 2009; Steinbach et
al., 2004).
The LIA (LUMItest) and the Kryptor assays have been utilized for most of the
clinical studies examining the clinical utility of measuring PCT to date. A multi-center
study compared the two assays for assay characteristics including within- and betweenrun estimates of precision, linearity, functional assay sensitivity, and a comparison of
PCT values on patients’ samples. The study found that the main differences between the
assays were that the LUMItest, being a manual assay, required more time to obtain
results. Furthermore, the functional sensitivity of the LUMItest was higher (0.30 ng/mL,
although some studies have shown it to be as low as 0.1 ng/mL) than that of the
KRYPTOR assay (0.04 ng/mL). The functional assay sensitivity is the lowest
concentration of PCT that can be analyzed with a coefficient of variation (CV) less than
or equal to 20%. The reference range for the two assays differs due to the functional
sensitivities. The reference range for normal (non-infected) subjects is <0.3 ng/mL for the
LUMItest assay and <0.05 ng/mL for the KRYPTOR assay. The analytical measurement
range for the KRYPTOR assay extends only to 50 ng/mL, while the LUMItest assay can
measure PCT concentrations up to 500 ng/mL. However, the instrumentation for the
KRYPTOR assay has automatic dilution protocols that increase the measurement range
up to 5000 ng/mL. The within-run and between-run precision of the KRYPTOR assay
was superior to the LUMItest assay. Within-run precision CVs were 3.14% - 4.56% (at
concentrations of 18.3 ng/mL and 0.26 ng/mL, respectively) for KRYPTOR vs. 3.14% –
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6.83% (at concentrations of 1.69 ng/mL and 15.70 ng/mL, respectively) for LUMItest
and between-run was 5.09% - 8.34% (at concentrations of 3.40 ng/mL and 9.18 ng/mL,
respectively) for the KRYPTOR and 6.28% - 16.44%, (at concentrations of 15.77 ng/mL
and 0.32 ng/mL, respectively) for the LUMItest. The highest correlation between the
LUMItest and the KRYPTOR assays was in the 0 – 50 ng/mL range, which is the
common measurement range for both assays with undiluted specimens. Linear regression
analysis on PCT results obtained on patients’ samples demonstrated r = 0.92 in the 0.3 –
50 ng/mL range (n = 534) and r = 0.91 for all data (n = 696). The conclusion was that
there should be no clinically relevant difference between PCT values obtained by the two
assays (Steinbach et al., 2004).
Siemens Healthcare Diagnostics has developed the BRAHMS PCT assay for their
ADVIA Centaur Immunoassay Analyzer. The assay has not yet been approved for use in
the US by the FDA but has been approved by the European Union (EU) regulatory
agency for use in Europe, Australia, and Canada. The assay is a one-pass antibody
sandwich immunoassay that uses an anti-fluorescein isothiocyanate-labeled ((FITC)
monoclonal antibody covalently bound to paramagnetic particles (PMP), two fluorescent
capture monoclonal antibodies, and an acridinium ester (AE)-labeled monoclonal
antibody. The PCT molecule is sandwiched between fluorscein labeled antibodies and
acridinium ester labeled antibodies with the whole complex held to an anti-fluorscein
labeled paramagnetic particle (solid phase structure). When the acridinium labeled
complex is exposed to acid and then base reagents a chemiluminescent reaction occurs
which produces a flash of light that is measured in RLUs. The RLUs are directly
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proportional to the amount of PCT in the serum ("Advia centaur immunoassay system
reference manual", 2003; "Advia centaur and advia centaur XP systems - procalcitonin
(PCT)", 2010).
The ADVIA Centaur BRAHMS PCT (CenPCT) has been compared to the
BRAHMS KRYPTOR assay in a 600 patient study in which single replicate serum
samples were assayed using each method. The specimen concentration ranged from 0.01
ng/mL to 573 ng/mL. Regression analysis of the results produces a correlation coefficient
(r) of 0.993 and a slope of 1.00 and an intercept of -0.04. Further studies produced a
functional assay sensitivity of <0.05 ng/mL. A normal population study resulted in an
average PCT value of 0.02 ng/mL (Per package insert the normal range is reported as
<0.1 ng/mL.). The analytical range of the CenPCT is 0.02 – 75.0 ng/mL. The ADVIA
Centaur has an automatic dilution protocol that allows for an increase in the measurement
range of up to 1440 ng/mL. The within-run precision CVs for the CenPCT were 1.1% 6.1% (at concentrations of 33.77 ng/mL and 0.06 ng/mL, respectively). The between-run
precision CVs for the CenPCT were 3.3% - 8.6% (at concentrations of 33.77 ng/mL and
0.06 ng/mL, respectively) (Aso, Baker, Freeman, & Navarro, 2009). Table 1 shows a
summary of the BRAHMS KRYPTOR and ADVIA BRAHMS PCT assays.
PCT as a Biomarker of Bacterial Infection or Sepsis
Assciot. Gendrel, Carson, Raymond, Guilbaud, and Bohuon (1993) first suggested
procalcitonin could be a marker of bacterial infection in 1993 when they found increased
concentrations of PCT in pediatric patients with bacterial infection (Bohuon, 2000; Carrol
et al., 2002) . In a subsequent study by Dandonna in 1994, healthy volunteers received a
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Table 1: KRYPTOR vs. ADVIA Centaur Assays for SPCTC
BRAHMS KRYPTOR PCT ADVIA Centaur BRAHMS PCT
Functional sensitivity
0.04 ng/mL
<0.05 ng/mL
Normal population
<0.05 ng/mL
0.02 ng/mL
Reference range
<0.05 ng/mL
<0.1 ng/mL
Analytical range
0.05 – 50 ng/mL
0.02 – 75 ng/mL
Range with auto-dilution
5000 ng/mL
1440 ng/mL
Within run CVs
3.14% - 4.56%
1.1% - 6.1%
Between run CVs
5.09% - 8.34%
3.6% - 8.6%

bolus of endotoxins after which SPCTCs were measured at defined intervals. PCT
concentrations had started to rise by three hours, reached a plateau by six hours, and
remained at these levels for up to 24 hours (Bohuon, 2000; Carrol et al., 2002).
In a case report of a 76 year old female who received an intravenous (IV) solution
contaminated (probably resulting from improper storage of the IV solution between dose
administrations) with Acinetobacter baumanii, PCT rapidly increased in the blood
following development of systemic infection (Brunkhorst, 1998). The PCT was
undetectable at 1.5 hours after the injection, became detectable at 2.5 hours, and peaked
at 13.5 hours. Serial measurements of PCT during follow-up days determined that the
PCT half-life is 22.5 hours (Brunkhorst, Heinz, & Forycki, 1998).
In a study in which seven healthy volunteers were administered intravenous
solutions containing endotoxins from Escherichia coli 0113:H10:k, PCT was not
detectable at two hours post injection but was detectable in all samples at 4 hours. Values
peaked between 8 - 12 hours post injection and remained high at 24 hours (Dandona et
al., 1998).
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Studies examining the elimination rate of PCT indicate that the approximate halflife of PCT is 30 hours for patients with normal renal function. The median PCT half-life
in patients with renal dysfunction was 33.1 – 44.7 hours. While patients with renal
dysfunction may have a longer PCT half-life, the kidneys do not appear to be the major
pathway of PCT elimination from the blood (Meisner, Schmidt, Huttner, &
Tschaikowsky, 2000; Meisner, Huettemann, Schmidt, Hueller, & Reinhart, 2001). These
results would suggest that PCT can be used to identify bacterial-induced systemic
inflammation.
Studies to demonstrate the clinical utility of PCT as a biomarker of bacterial
infection have taken two approaches: 1) use of PCT as a diagnostic biomarker of
infection and 2) use of PCT to confirm the appropriateness of specific antibiotic therapy
and patient outcomes. Studies of PCT as a diagnostic biomarker of infection have looked
at patients with respiratory tract infections, peritonitis, meningitis, and post-surgical
infections in the setting of the emergency department (ED), intensive care unit (ICU), and
general hospital wards. There have been at least nine randomized trials (seven singlecenter and two multi-center) looking specifically at the use of PCT to guide antibiotic
therapy.
Several investigators have examined the utility of measuring PCT in patients that
present to the ED, ICU, and general hospital wards with signs of infection or sepsis. In
two studies, subjects were admitted to the ICUs for their respective hospitals with a
suspected diagnosis of infection. The studies classified the subjects based upon their
SIRS status into one of four groups: SIRS, sepsis, severe sepsis, or septic shock. In a
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study by Brunkhorst, Wegscheider, Forycki, & Brunkhorst (2000), a PCT cutoff of 2.0
ng/mL predicted severe sepsis with an estimated 96% sensitivity and 86% specificity
using receiver operator curve (ROC) analysis. A cutoff of 11.6 ng/mL predicted septic
shock with an estimated 53% sensitivity and 72% specificity. Mean PCT values for the
groups were 0.41 ng/mL (SIRS), 0.53 ng/mL (sepsis), 6.91 ng/mL (severe sepsis), and
12.89 ng/mL (septic shock). A study by Harbarth, et al. (2001) had similar results.
Investigators determined that a PCT cutoff of 1.1 ng/mL predicted sepsis with 97%
sensitivity and 78% specificity using ROC analysis. The mean PCT values for the groups
were 0.6 ng/mL (SIRS), 3.5 ng/mL (sepsis), 6.2 ng/mL (severe sepsis), and 21.3 ng/mL
(septic shock).
Cheval, C., Timsit, J. F., Garrouste-Orgeas, M., Assicot, M., De Jonghe, B.,
Misset, B., et al. (2000) evaluated the use of PCT to assess infection in the
medical/surgical ICU setting. The study included four groups of acutely ill patients
admitted to the ICU. Sixty patients were assigned to one of four groups: 1) shock (with
bacterial infection), 2) non-septic shock (with no bacterial infection), 3) infected, and 4)
control (no evidence of infection). Patients with proven bacterial infection (groups 1 – 3)
had mean PCT concentrations of 72 ng/mL which was significantly higher than the PCT
results for patients in the control group (Group 4) at 2.9 ng/mL (p-value = 0.0003).
Patients with shock and a confirmed bacterial infection (Group 1) had higher mean PCT
values than those with shock and no confirmed infection (Group 2), 89 ng/mL and 2.9
ng/mL, respectively (p-value = 0.0004). A SPCTC of at least 20 ng/mL predicted positive
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blood cultures in infected patients with sensitivity of 89 + 21% and specificity of 83 +
15%.
A study by Guven, H., Altintiop, L., Baydin, A., Esen, S., Aygun, D., Hokelek,
M., et al. (2002) enrolled 34 patients that were admitted to the ED between January 1999
and September 2000, who were at risk for sepsis due to hospitalization or insertion of
intravascular and/or urinary catheters. All patients met at least two criteria for SIRS. The
patients were divided into two groups: sepsis not suspected and sepsis suspected. The
sepsis not suspected group included 15 patients who had minor infections (upper
respiratory tract, otitis media, or gastroenteritis) who were observed in the ED for 24
hours and then discharged. The sepsis suspected group included 19 patients with a history
of previous cerebrovascular disease, chronic obstructive pulmonary disease, diabetes
mellitus, or previous hospitalizations but had no documented bacterial infection. The
patients in the sepsis not suspected group all had negative blood cultures and an average
SPCTC of 0.23 ng/mL. In the sepsis suspected group, 13 of 19 patients had positive
blood cultures and an average PCT value of 67.89 ng/mL. Two patients with negative
blood cultures had near normal PCT values (normal 0 – 5 ng/mL) while two others had
extremely high values (approximately 500 ng/mL) and were diagnosed with acute
pancreatitis (Guven et al., 2002).
In a study by Brunkhorst, Eberhard, & Brukhorst (1999), 27 patients with adult
respiratory distress syndrome (ARDS) were prospectively studied to determine the ability
of PCT to discriminate between septic and non-septic causes of ARDS: 10 patients
developed ARDS due to injuries to the lung and 17 developed ARDS due to bacterial

33
infection. Serum PCT concentrations were measured every four to six hours for 72 hours
immediately following a diagnosis of ARDS. PCT values in patients with non-septic
ARDS averaged approximately 1.0 ng/mL (with no values higher than 2.9 ng/mL), while
the PCT values in septic ARDS patients were all greater than 5.0 ng/mL (Brunkhorst et
al., 1999).
In a study by Luyt, C., Guerin, V., Combes, A., Trouillet, J., Ayed, S. B., Bernard,
M., et al. (2005), 63 prospectively enrolled patients with ventilator-associated pneumonia
(VAP) were studied to determine if PCT kinetics could serve as a prognostic marker of
infection in these patients. In the study, 38 patients had unfavorable outcomes (death,
VAP recurrence, or extrapulmonary infection requiring antibiotics before Day 28) and 25
patients had favorable outcomes (not meeting one of the unfavorable outcome
requirements). Median PCT values were significantly higher for unfavorable outcome
group than for the favorable outcome group on days 1, 3, and 7. On Day 1, a PCT value
>1.0 ng/mL had an odds ratio of 12.3 of being associated with an unfavorable outcome.
Later time points demonstrated increasing odds ratios with an odds ratio of 24.6 on day 3
for a PCT > 1.5 ng/mL and 64.2 on day 7 for a PCT > 0.5 ng/mL (Luyt et al., 2005).
Reith, Mittelkotter, Wagner, & Thiede (2000) assessed serum PCT as a measure
of the severity in patients with septic abdominal illnesses. In this prospective study, serial
measurements of PCT were carried out in 246 patients with infective or septic episodes
and in 66 patients with elective operations who served as controls. The causes of
infective peritonitis in this study included pancreatitis, colon perforation, abscess, trauma,
and mesenteric infarction. In the peritonitis group, 59 of the 246 patients died. The mean
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PCT value in patients who died rose from 4.2 ng/mL initially, to 13.2 ng/mL at time of
death. The remaining peritonitis subjects had a mean initial PCT value of 2.1 ng/mL that
rose to 4.8 ng/mL on day 4 then decreased to 0.4 ng/mL at end point (day 10 postoperatively, 3 months post-operatively for patients with metastasis, or death). PCT values
for the control group who had no signs of post-operative infection or sepsis were within
the reference range (0.1 – 0.8 ng/mL) for 98% of the samples tested (424 of 431
samples). The remaining seven samples had values between 0.8 and 1.2 ng/mL. The
results of this study indicated that PCT was elevated in septic patients with peritonitis and
that a reduction of PCT during their clinical course was predictive of survival (Reith et
al., 2000).
PCT has been shown to be a strong predictor for distinguishing bacterial and nonbacterial meningitis (such as viral, fungal, drug related, and tick-borne disease related). In
a study by Dubos, et al. (2008), data from 198 children admitted to six pediatric ED or
ICU units in five European countries were retrospectively examined to determine the
usefulness of PCT as a marker of bacterial meningitis. At a 0.5 ng/mL threshold, PCT
had 99% sensitivity and 83% specificity for distinguishing between bacterial and aseptic
meningitis. Ninety-six of the 198 patients studied had bacterial meningitis confirmed by a
positive culture but only 75% had a positive gram stain report. The bacterial organisms
identified in these patients included Neisseria meningitides, Streptococcus pneumoniae,
H influenzae, and Streptococcus pneumoniae. The median PCT value in patients with
bacterial meningitis was 21.5 ng/mL while the median PCT value in patients with nonbacterial meningitis was 0.3 ng/mL (p-value < 1 x 10-6) (Dubos et al., 2008).
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In two studies of post-operative patients, PCT was examined as a biomarker of
infection post surgery. Falcoz, P.-E., Laluc, F., Toubin, M.-M., Puyraveau, M., Clement,
F., Mercier, M., et al. (2005) studied patients after thoracic surgery and found a mean
PCT value in 132 non-infected patients of 0.63 ng/mL versus 3.6 ng/mL for 25 patients
who developed a post-operative infection (p-value = 0.0001). Meisner, Tschaikowsky,
Hutzler, Schick, & Schuttler (1998) studied 130 patients with different types of surgeries,
measuring PCT pre-operatively and for five days post-operatively. Patients were assigned
to one of five groups based upon the type of surgery performed: 1) minor surgery - hip
replacement, peripheral vascular surgery, and general surgery, 2) minor abdominal
surgery - cholecystectomy, 3) abdominal surgery of the intestine - resection of the colon,
sigma, and rectum, and gastrectomy, 4) major abdominal or thoracic surgery esophagectomy, Whipple procedure, and major vascular surgery, and 5) cardiac and
thoracic surgery - coronary artery bypass, resection of the lung, and diagnostic
thoracotomy. For patients with a normal post-operative course without infection or sepsis
(n = 117), the median PCT values for all groups were < 1.0 ng/mL except the surgery of
the intestine (group three) that had a median value of 1.5 ng/mL for patients with a
normal post-operative course without infection or sepsis. Thirteen patients (a
heterogeneous mix of the abdominal surgery of the intestine, major abdominal or
thoracic, and cardiac and thoracic surgery groups) had abnormal post-operative courses.
An abnormal post-operative course was defined as fulfilling SIRS or sepsis criteria, any
clinical sign of infection, increased body temperature above 380C after post-op day 2,
extubation after post-op day 1, requiring catecholamine therapy, cardiac insufficiency,
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pulmonary infiltrates, local wound infection, or reoperation. This group had a median
PCT value of 6.48 ng/mL while only one patient had an identified bacterial infection
(Meisner et al., 1998). Both studies showed a general increase in PCT immediately
following surgery. The amount of increase observed was dependent upon the type of
surgery performed. However, in both studies, the PCT level was lower in patients who
did not develop an infection or sepsis post-operatively. The cause of the higher PCT
values in the non-septic patients (from both studies) is not entirely understood. Both
authors noted these increases and speculated that they may be a result of the type of
surgery (the majority of the surgeries in these patients were cardiac and thoracic in
nature) and due to lung involvement. An increase in PCT after lung injury in the absence
of infection has been noted (Falcoz et al., 2005; Meisner et al., 1998).
The above studies indicated that PCT is a good predictor of bacterial infection or
sepsis in most cases. The studies also showed that PCT was not an absolute indicator of
infection and should be used in conjunction with other infection indicators.
PCT Use to Guide Antibiotic Therapy
Not only is serum PCT concentration measurement being used as an indicator of
infection, but it is also being used to guide antibiotic treatment. Studies have shown that
PCT-guided therapy has substantially reduced the amount of antibiotic used by
decreasing the prophylactic use of antibiotics when a bacterial infection is suspected but
not actually present and shortening the length of antibiotic treatment in bacterial
infections that respond to therapy. The reduced number of antibiotic treatment days lead
to fewer antibiotic adverse effects without increasing the number of adverse events
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(Bouadma et al., 2010; P. E. Charles et al., 2009; Christ-Crain et al., 2004; Schuetz,
Christ-Crain, & Muller, 2009; Tang, Huang, Jing, Shen, & Cui, 2009).
Studies have compared standard of care (SOC) antibiotic therapy to PCT guided
antibiotic therapy in patients with lower respiratory tract infections (LRTI). Diagnoses
that are related to LRTI include acute bronchitis, acute exacerbations of chronic
pulmonary disease, asthma, and pneumonia. Patients presenting with signs and symptoms
of LRTI are often treated with antibiotics, without clear evidence of a bacterial infection.
LRTIs are mainly viral in nature. LRTI is the leading cause for antibiotic prescriptions in
the Western hemisphere and contributes to increasing bacterial resistance to antibiotics
(Christ-Crain et al., 2004; Schuetz et al., 2009; Schuetz et al., 2009; Schuetz, ChristCrain, & Muller, 2009).
Christ-Crain, et al. (2004) conducted a prospective randomized controlled single
blinded intervention trial with 243 subjects enrolled in the study. The subjects were
randomly assigned to either the SOC (standard antimicrobial therapy) or PCT guided
groups. In the PCT group, the physician first had to declare his/her intention to prescribe
antibiotics after which they were advised to follow the PCT algorithm for prescribing
antibiotics. The algorithm using the serum PCT concentration was:


0.1 ng/mL or less indicates absence of bacterial infection and antibiotics are
strongly discouraged



0.1 – 0.25 ng/mL indicates bacterial infection is unlikely and antibiotics are
discouraged
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0.25 – 0.5 ng/mL indicate possible bacterial infection and the doctor is advised to
initiate antibiotic therapy



0.5 ng/mL or greater is suggestive of a bacterial infection and antibiotic treatment
is strongly suggested.

For patients on antibiotics at the time of hospital admission, discontinuation of antibiotic
therapy was recommended if the PCT value was less than 0.25 ng/mL (Christ-Crain et
al., 2004).
The second study is the Procalcitonin Guided Antibiotic Therapy and
Hospitalization in Patients with Lower Respiratory Tract Infections: The ProHOSP
Study. This was an investigator initiated multi-center randomized controlled trial with
six participating tertiary care hospitals in Switzerland. Patients were randomized into
PCT-guided treatment group using the PCT cut-off ranges described above or SOC
treatment to initiate or stop antibiotic treatment (Schuetz et al., 2009).
Both studies found that the duration of antibiotic therapy was significantly less in
the PCT-guided antibiotic therapy groups compared to the SOC groups (Table 2) with no
difference in the rate of adverse outcomes (death). The ProHOSP study also determined
that the PCT-guided treatment group had fewer adverse effects (including nausea,
diarrhea, and rash) from antibiotics than SOC (133 vs. 193 respectively), a decrease of
28.2% (Christ-Crain et al., 2004; Schuetz et al., 2009).
The Procalcitonin to Reduce Antibiotic Treatments in Acutely ill patients
(PRORATA) trial was a prospective parallel group study undertaken in France to assess
critically ill patients with suspected bacterial infections. The study was a multi-center
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Table 2: Published Studies of PCT Guided Antibiotic Therapy vs. SOC
Antibiotic Treatment Group
SOC

PCT guided

Percent
difference

119
12.8
4

124
10.9
4

-14.8%
0%

688
8.7
33

671
5.7
34

-34.8%
3.0%

314
9.9
64

307
6.1
65

-38.4%
1.6%

Christ-Crain
# patients
Mean days antibiotic treatment
Died
ProHOSP
# patients
Mean days antibiotic treatment
Died
PRORATA
# patients
Mean days antibiotic treatment
Died

study of patients in the medical and surgical ICUs of five university-affiliated hospitals
and one general hospital. All adults with suspected bacterial infections in the ICUs were
eligible for the study if they had not been receiving antibiotics before the study. Patients
were randomly assigned to either a PCT-guided antibiotic therapy group or a SOC group.
The results of this study (see Table 1) were similar to the previously described studies in
that the PCT-guided therapy group - shorter average number of days of antibiotic
exposure without affecting the rate of adverse outcomes (Bouadma et al., 2010). Table 1
summarizes the results from the three aforementioned studies.
In an observational study by Charles et al., (2009) of 180 patients in France, PCT
was monitored over four days, as part of the patients’ standard of care and the change in
PCT values were related to appropriateness of antibiotic therapy. Patients in the ICU who
had bacteremia, community-acquired pneumonia, or ventilator-associated pneumonia
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were prospectively enrolled in the study. The appropriateness of antibiotic therapy was
determined by retrospective chart review to obtain antimicrobial susceptibility testing
reports by an infectious disease expert who was blinded to the PCT values and patient
outcomes. PCT values were also obtained from the retrospective chart review. The
authors concluded that appropriate antibiotic therapy (the isolated pathogen(s) was (were)
susceptible to at least one drug administered at the onset of sepsis according to the
corresponding susceptibility testing report) was associated with a greater decrease in PCT
values in the first 48 hours of antibiotic treatment (Table 3). The patient group that had
appropriate antibiotic therapy had a greater decrease in mean PCT values between days
two and three, -3.9 ng/mL, than the inappropriate antibiotic therapy group, +5.0 ng/mL (p
<0.01). The study also found that there was a greater rise in mean PCT values between
days one and two for the inappropriate antibiotic therapy group, +5.2 ng/mL than for the
appropriate antibiotic group, +1.7 ng/mL (p = 0.20). They noted, however, that their
study was a single center study and that a prospective study would be needed to assess
PCT and clinical findings as an indicator of the effectiveness of antibiotic therapy and the
use of more effective therapies (Charles, 2009).
Table 3: Comparison of SPCTC Values in Appropriate and Inappropriate Antibiotic
Therapy

Number of subjects
Average Day 1 PCT [ng/mL]
Average Day 2 PCT [ng/mL]
Average Day 3 PCT [ng/mL]
Average Day 4 PCT [ng/mL]

Antibiotic Therapy
Appropriate Inappropriate
135
45
27.2
29.6
27.4
40.9
24.4
34.4
17.3
32.4

p-value
0.92
0.09
0.12
0.03
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Overall these studies and others (Bouadma et al., 2010; Tang et al., 2009)
indicate that PCT can be used to decide if antibiotic therapy is required in the case of
suspected bacterial infection. PCT may be useful in determining if antibiotic therapy is
appropriate prior to the availability of antimicrobial susceptibility results.
Procalcitonin and Liver Disease
Initiation of antibiotic therapy as soon as possible is critical in all cases of
bacterial infection and sepsis. However, in the ALF/ALI population this can be a doubleedged sword. Many commonly used antibiotics are known to be metabolized by the liver.
Examples include but are not limited to sulfa-related compounds, quinolones,
amoxicillin, and flucloxacillin. Giving a drug that is metabolized by the liver to a patient
with liver dysfunction can lead to drug toxicity. Some cases of ALF/ALI are caused by
use of antibiotics. The reasons that antibiotics are associated with liver injury are not
entirely understood (Murray, Hadzic, Wirth, Bassett, & Kelly, 2008). Therefore, giving
antibiotics to this population of patients is not always the best course of action. A clear
indication of need is of extreme importance in this situation. Therefore, a method of
determining the need for antibiotic use that is faster than the standard culture methods is a
worthwhile goal. Procalcitonin could prove to be highly useful for this group of patients,
to either identify or exclude bacterial sepsis.
There are few published studies on the measurement of serum procalcitonin in
patients with liver disease, and none specifically in patients with ALF or ALI. Previously
published studies included populations with cirrhosis (Bota, Van Nuffelen, Zakariah, &
Vincent, 2005; Connert, Stremmel, & Eising, 2003; Spahr, Morard, Hadengue, Vadas, &
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Pugin, 2001; Viallon et al., 2000), liver metastasis of non-liver primary solid tumors
(Matzaraki et al., 2007), and acute and chronic liver disease (Elefsiniotis, Skounakis et
al., 2006). The results of the cirrhosis studies present some conflicting data. Viallon et al.
(2000) enrolled 61 subjects: 21 with spontaneous bacterial peritonitis (SBP) and 40 with
sterile ascitic fluid (SAF). The severity of liver disease was similar in both groups with
the SBP patients having a mean Child-Pugh score of 11 and the SAF group having a
Child-Pugh score of 10. The Child-Pugh score is a standard measure of the severity of
chronic liver disease based on a three point evaluation of five features of cirrhosis: the
presence/severity of ascites and encephalopathy and the concentrations of albumin,
bilirubin, and INR. The maximum score is 15. The median PCT values from samples
taken at study admission prior to initiation of antimicrobial therapy were significantly
different between the two groups, with patients in the SBP group having a mean serum
PCT = 10.10 ng/mL while that of patients in the SAF group was 0.09 ng/mL (p-value =
0.0001) (Viallon et al., 2000). The serum PCT measurements appear to be a marker of
bacterial peritonitis in patients with liver disease.
Connert et al. (2003) enrolled 127 patients with cirrhosis. The subjects were
divided into three groups based upon bacteriological and clinical findings. Group I had 36
patients with decompensated liver disease (ascites, encephalopathy, variceal hemorrhages
are the classic features evidencing decompensation) with an infection. Group II had 64
patients with decompensated liver disease without an infection. Group III had 27 patients
with non-decompensated liver disease and without infection. The mean PCT values for
Groups II and III were lower (0.6 ng/mL and 0.4 ng/mL, respectively) than for Group I
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(2.8 ng/mL) (Connert et al., 2003). Thus, serum PCT measurements appear to be a
marker of infection in patients with cirrhosis.
Bota et al. (2005) studied 864 critically ill patients in the ICU, of which 79 were
patients with cirrhosis. The cirrhotic patients were divided into three groups based upon
severity of liver disease as measured by the Child-Pugh score. Table 4 illustrates that the
serum PCT concentrations did not appear to vary with the severity of liver disease. The
study did show a difference between infected and non-infected patient PCT values. Initial
mean PCT values were approximately 1.25 ng/mL in infected cirrhotic patients, 2.0
ng/mL in infected non-cirrhotic patients, 0.5 ng/mL in non-infected cirrhotic, and 0.4
ng/mL in non-infected non-cirrhotic patients, but there were no significant differences in
the PCT levels in relation to the severity of cirrhosis (Bota et al., 2005).
Table 4: SPCTC and Child-Pugh Score in Patients with Cirrhosis, With and Without
Infection
Controls
# subjects
Child-Pugh score
SPCTC [ng/mL] – initial

785

All
79

0.632

0.682

Patients with Cirrhosis
Inf NI Inf NI Inf
15 14
5-6
1.2 0.3

10 13
7-9
1.3 0.4

NI

13 14
10 - 15
1.1 0.4

Inf = Infection; NI = No Infection

Spahr et al. (2001) measured serum PCT concentrations in 10 patients with
cirrhosis and spontaneous bacterial peritonitis and in 10 patients with cirrhosis but
without spontaneous bacterial peritonitis. The mean PCT values for 10 patients with SBP
were 0.74 ng/mL vs. 0.2 ng/mL for 10 non-infected patients. The authors concluded that
PCT was not a good indicator of infection in this group of patients possibly because the
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absence of SIRS in the patients with SBP (Spahr et al., 2001). Therefore, serum PCT
measurements may not be a marker of infection in patients with liver disease, if the
infection is localized and the patient has not yet progressed to sepsis.
Matazaraki et al. (2007) studied the serum PCT concentrations in patients who
had solid tumors that had metastasized to the liver. This study included 15 healthy control
subjects (Group A), 21 patients with solid tumors that had not metastasized (Group B), 11
patients with liver metastasis (Group C), and 11 patients with generalized metastasis
(Group D). The PCT values were 0.284 ng/mL for Group A, 0.327 ng/mL for Group B,
0.690 ng/mL for Group C, and 1.030 ng/mL for Group D. Table 5 shows the comparisons
between the groups. PCT concentrations appear to increase with increasing degree of
metastasis to levels that are similar to those found in patients with confirmed infection or
sepsis. Further study will be required to determine if PCT can be used as a marker for
sepsis and possibly as a marker of disease progression in this population of patients
(Matzaraki et al., 2007).
Table 5: SPCTC in Patients with Liver Cancer

Group A (control)
Group B (solid tumor)
Group C (liver metastasis)
Group D (general metastasis)

Mean PCT Comparison to Comparison to
(ng/mL) Group C p-value Group D p-value
0.284
0.10
<0.001
0.327
0.117
0.004
0.690
0.199
1.030

Elefsiniotis, Skounakis, et al. (2006) evaluated the differences in serum PCT
concentrations between patients with acute and chronic liver disease. PCT was measured
in 106 consecutively hospitalized patients with liver disease at the time of admission. The
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etiology of liver disease included alcoholic hepatitis (Group A, n = 15), alcoholic
cirrhosis without hepatitis or bacterial infection (Group B, n = 20), decompensated
cirrhosis with proven bacterial infection (Group C, n = 16), uncomplicated viral hepatitiscirrhosis (Group D, n = 42), and acute icteric viral hepatitis (Group E, n = 13). The mean
SPCTCs were 0.40 ng/mL in Group A, 0.23 ng/mL in Group B, 9.80 ng/mL in Group C,
0.21 ng/mL in Group D, and 0.37 ng/mL in Group E. This study showed that while all
groups without indication of infection had initial PCT values that were slightly higher
than non-infected non-cirrhotic patients (LUMItest reference range PCT <0.3 ng/mL),
PCT values from groups A, B, C, and E were significantly lower than the PCT values of
the cirrhotic patients with infection (Group C) (Elefsiniotis et al., 2006).
Summary
All of the above studies, with the exception of the Spahr study, indicated that PCT
can be used to presumptively identify a bacterial infection in patients with liver disease.
However, none of the studies included patients with the most severe, acute liver disease,
those with ALF or ALI. The Elefsiniotis study looked at some acutely ill liver disease
patients some of whom might have met the diagnostic criteria of ALF or ALI, but none of
the groups as a whole appeared to have met the diagnostic criteria. All of the above
studies were small and none looked at how PCT relates to the severity of infection in
patients with ALF or ALI. In addition, none of the studies explored whether or not
SPCTCs change in response to successful treatment of bacterial infection in acute liver
disease patients.
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Significance of This Study
Procalcitonin appears to be a robust marker for bacterial infection. The above
studies have shown that SPCTC is a good indicator of infection in the general population
and is useful in monitoring antimicrobial therapy. However, it has not been extensively
studied in the setting of acute liver injury or liver failure. The present proposed study
investigated how SPCTCs vary in patients with ALF and ALI depending upon the
severity of illness. Next, it will examine the utility of serum PCT concentrations as an
indicator of bacterial infection in ALF and ALI patients. Lastly, the study investigated
whether serum PCT values differ between ALF and ALI patients who are treated for
bacterial infection and who achieve transplant free survival (alive at 21 days without
transplant) and those treated for bacterial infection and who had a liver transplantation or
died within the 21 day period of ALF or ALI study.

CHAPTER 3: METHODS

This chapter describes the research design, methodology, and analyses used to
determine whether procalcitonin is effective as a biomarker of infection/sepsis in the
ALF/ALI patient populations. The ALF and ALI databases, sample selection, and
independent and dependent variables in each section of the study are described. Statistical
methods used to analyze the data are described. Limitations of the study are discussed.
Research Design
This study was a retrospective, non-experimental study with three parts. A true
experimental study was impractical due to the low incidence of ALF and ALI cases in the
general population. Because the study used retrospective data and samples, the
independent variable for this study, infection, could not be manipulated, fitting the
description of non-experimental as described by Polit and Beck (Polit & Beck, 2008).
Specific Aim 1 of the study examined the relationship between the severity of infection
and SPCTC. Specific Aim 2 examined the relationship between the presence or absence
of infection and SPCTC. Finally, Specific Aim 3 examined the differences in SPCTCs
between infected ALF and ALI patients with transplant free survival (TFS - alive at
discharge or 21 days) and infected ALF and ALI patients who died or received a liver
transplant (DoT) within 21. The changes in the SPCTC values across the seven days of
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the ALF/ALI study specimen collection were also compared between the TFS and DoT
subjects.
Specific Aims, Hypotheses, and Study
There are three main aims for this study:
Specific Aim 1: To determine if 1) there are differences in SPCTCs between noninfected ALF and ALI patients and non-infected chronic liver disease patients, 2)
between infected and non-infected ALF and ALI patients, and 3) between ALF
and ALI patients and those of the general population with different severities of
infection.
As noted by O’Grady, et al. (2008) and Harbarth, et al. (2001), SPCTCs can be used to
denote the severity of infection in patients with definite or suspected bacterial infections.
Can PCT be used in the ALF/ALI patient population to detect bacterial infections? Does
liver disease affect the SPCTCs of liver disease patients with or without infection?
H0: There is no difference in SPCTCs between non-infected ALF/ALI patients
and non-infected chronic liver disease patients.
H0: There is no difference in SPCTSs between non-infected patients with liver
disease (chronic and ALF/ALI) and non-infected patients in the general
population (i.e., SPCTC <0.1 ng/mL.
H0: There is no difference in SPCTC between ALF/ALI patients with different
degrees of severity of infection (i.e., Neg SIRS, SIRS, sepsis, severe sepsis, and
septic shock).
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These hypotheses were tested by measuring SPCTC in ALF/ALI patients with a
documented history of infection, ALF/ALI without an infection, and chronic liver disease
patients without an infection. The results were analyzed according to the presence or
absence of infection and according to the severity of infection status based upon clinical
signs and symptoms.
Specific Aim 2: Determine the utility of SPCTC as a screening biomarker for
infection in ALF/ALI patients
Does a change in SPCTC predict the onset of bacterial infections/sepsis in the ALF/ALI
patient population?
H0: There is no difference in SPCTC in ALF/ALI patients between the first day a
positive culture was collected and the three days prior to the positive culture.
By measuring SPCTC on the days prior to diagnosis of infection and on the day of
infection, we determined if PCT will give an earlier indication of infection than clinical
symptoms.
Specific Aim 3: Determine if SPCTC in ALF and ALI patients with bacterial
infection on Day 1 of the ALF or ALI study is associated with patient outcomes.
Can changes in PCT be used to monitor progression or resolution of bacterial infection in
the ALF/ALI patients?
H0: There is no difference in SPCTC between ALF and ALI patients with a
bacterial infection/sepsis who have transplant free survival and those who die or
receive a liver transplant.
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H0: There is no difference in changes in the serial SPCTCs between ALF/ALI
patients with a bacterial infection/sepsis who have transplant free survival and
those who die or receive a liver transplant.
By measuring SPCTC in ALF and ALI patients who have known infections, we
determined if there were differences in the SPCTC between patients who died or received
a liver transplant and those with transplant free survival. In studies of SPCTC in subjects
with pathologies other than liver disease and sepsis/bacterial infections, monitoring
SPCTC has shown the ability to successfully decrease the length of antibiotic use
(Bouadma et al., 2010; Kollef, 2010). We analyzed serial SPCTC in patients who were
diagnosed with infection/sepsis on Day 1 of study and compared the results between
those with transplant free survival and those who died or received a liver transplant.
Changes in the serial values will also be analyzed to determine if there are differences
between the two groups.
Databases
Samples and data were obtained from four liver disease sample repositories and
databases maintained by the University of Texas Southwestern Medical Center (UTSW)
(Table 6). Acute liver disease samples and data were obtained from the ALF and ALI
databases and sample repositories. Chronic liver disease data and samples were obtained
from the Liver Disease database and sample repository and from the Nucleic Acid,
Serum, and Tissue Repository for the Study of Liver Diseases database and sample
repository.
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Table 6: Databases

Database
Acute Liver Failure

Collection
Started
Jan. 1998

Acute Liver Injury

Oct. 2008

Liver Disease Database Dec. 2005

Nucleic Acid, Serum,
and Tissue Repository
for the Study of Liver
Diseases Database

1996

Subjects
Enrolled
Prior to
Description
10-1-10
A multi-center NIH supported study
1700
to collect clinical information,
serum/plasma, DNA, and tissue
samples from patients with ALF
A multi-center NIH supported study
163
to collect clinical information,
serum/plasma, DNA, and tissue
samples from patients with ALI
An Investigator initiated study at
475
UTSW to collect information and
serum/plasma samples from subjects
who may qualify for clinical trials or
are at high risk for developing liver
disease.
Investigator initiated study at UTSW
206
to collect data/samples to support
translational research in liver
diseases.

Acute Liver Failure Database
The U.S. Acute Liver Failure Study Group (USALFSG) was established in 1998
with pilot funding from the FDA and supported by the National Institute of Health (NIH)
continuously since that time. The group proposed two aims: to prospectively collect
detailed clinical information, serum, DNA, and tissue samples from patients with ALF
and to develop controlled trials of innovative therapies for ALF (Lee et al., 2008; Lee &
Seremba, 2008). The USALFSG is currently composed of 13 clinical sites, reduced from
a maximum of 23 clinical sites prior to 2010. From January 1998 to October 2010, 1700
adult ALF patients have been prospectively enrolled in the study. Inclusion criteria
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defining ALF are the presence of coagulopathy (PT > 15 seconds or INR >1.5) and any
grade of hepatic encelphalopathy (HE) that occurs within 26 weeks of the first onset of
symptoms. The patients may not have any previously diagnosed liver disease, with the
exception of chronic hepatitis B or Wilson’s disease as defined earlier (Lee et al., 2008).
Due to the altered mental status of the patients caused by HE, informed consent must be
obtained from the next of kin to be enrolled in the ALF study.
Patients are enrolled into the ALF study for a maximum of 21 days with two
annual follow-up visits. Clinical and demographic information, medical history, and
medication history are obtained from the medical record for days 1 – 7 and 21 (or day of
discharge, transplant, or death) and at each follow-up visit. The information is recorded
on the study case report form (CRF). If required, information may be requested from the
patient’s primary care physician, once a signed medical records release form is obtain.
All information is entered into the USALFSG database.
Blood samples are collected on days 1 – 7, unless the patient is discharged, dies,
or is transplanted. The blood samples are centrifuged to remove the cells and 500 µL
aliquots of serum or plasma are frozen at -20o C or colder in small cryo vials. Samples are
stored at the collecting facility until sent to the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) sample repository. The NIDDK repository
stores the samples at -70o C.
Acute Liver Injury Database
The Acute Liver Injury Study is an extension of the ALF study in which patients
present to the hospital with acute liver disease but do not exhibit any signs of hepatic
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encephalopathy at the time of admission. If encephalopathy occurs during the course of
the study, the patient may be consented and enrolled in the ALF study. In this case, the
data would then be collected using the ALF protocol. The purpose of the ALI study, like
the ALF study, is to collect clinical information, serum, DNA, and tissue samples from
patients with ALI, and to develop controlled trials of innovative therapies for ALI. The
ALI subjects are prospectively enrolled into the study at the same clinical sites that are
enrolling ALF patients. The data and sample collection plan is similar to that described
for ALF. Data and blood samples are collected on days 1 – 7 (or until discharge, death,
transplant, or transfer to the ALF study). Follow-up data is also collected at day 21, six
weeks, and 12 weeks if possible. The ALI sub-study was started in October 2008 and has
enrolled 163 subjects through September 2010.
Although the diagnostic criteria for acute liver injury are the same as for acute
liver failure only without HE, the inclusion criteria for the ALI database differ slightly
from those of ALF. The inclusion criteria for ALI are: serum ALT greater than or equal
to 10 times the upper limit of normal, total serum bilirubin greater than or equal to 3.0
mg/dL, coagulopathy (PT greater than 20 seconds or INR greater than 2.0), acute hepatic
illness of less than 26 weeks and no evidence of encephalopathy. Patient with
acetaminophen etiology should have hepatic illness of less than two weeks duration.
Liver Disease Database
The primary purpose of the Liver Disease database (LDD) is to allow for contact
between study personnel at the University of Texas Southwestern Medical Center at
Dallas (UTSW) Clinical Center for Liver Disease (CCLD) and patients who have liver
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disease and may wish to qualify for clinical trials or who are considered at high risk of
developing liver disease (subjects with high risk behavior and spouses of patients with
hepatitis). The secondary purpose of the database/sample repository is to provide serum
samples for various liver disease research projects, and to characterize subjects based on
their specific disease etiology such as viral hepatitis genotype. While the study enrolls
subjects with all types of liver disease and some without apparent liver disease, it is
composed primarily of subjects with viral hepatitis, predominantly hepatitis C. The study
received initial IRB approval in December 2005, and has prospectively enrolled 475
subjects as of Oct. 2010.
Once a patient is identified as a possible study subject and informed consent is
properly executed, a short questionnaire is filled out. The questionnaire is used to collect
demographic information including contact information and liver disease etiology. If the
subject consents, a blood sample is collected so that serum and plasma can be stored for
later use to categorize the subject or for research protocols involving liver disease. The
subject may elect to not have a blood specimen collected at the time of enrollment but
may be asked to have one collected at a later time if they are interested in a potential
treatment study and wish to be pre-screened for the trial. Remnant samples are stored for
future testing. The blood samples are centrifuged to remove the cells and 500 µL aliquots
of serum or plasma are frozen at -20o C or colder in small cryo vials. Samples are stored
at UTSW Liver Research Laboratory at -70o C.
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Nucleic Acid, Serum, and Tissue Repository for the Study of Liver Diseases Database
The primary purpose of the Nucleic Acid, Serum, and Tissue Repository for the
Study of Liver Diseases (NSTLD) study is to gain a better understanding of possible
causes of the development and progression of liver diseases in order to develop new
treatments. The data/sample repository provides support for translational research in liver
diseases within the UTSW Division of Digestive and Liver Diseases. While the study
enrolls subjects with all types of liver disease and controls, the database is composed
primarily of subjects with primary biliary cirrhosis. The study received initial IRB
approval in 1996, and has prospectively enrolled 206 subjects as of Oct. 2010.
Once a patient is identified as a possible study subject and informed consent is
properly executed, a short questionnaire is filled out. The questionnaire is used to collect
demographic information including contact information and liver disease etiology. Blood
and tissue samples are collected as part of this study. The blood samples (for obtaining
serum or plasma collection) are centrifuged to remove the cells and 1000 µL aliquots of
serum or plasma are frozen at -70o C or colder in small cryo vials. Samples are stored at
the UTSW Department of Digestive and Liver Diseases Laboratory at -70o C.
Sampling
This study has three components. Each part of the study is related to one of the
three specific aims. Sample populations are described for each group.
Specific Aim One
The first step requires the identification of the patient samples used for this
section of the study. As described above, a patient can be classified as having SIRS,

56
sepsis, and severe sepsis based upon their clinical biodata. An algorithm (see Appendix
A) based upon the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions
Conference definitions of SIRS, sepsis, severe sepsis, and septic shock was used to
determine which classification each subject fit into during each of the first seven days of
the study for all subjects in both the ALF and ALI databases. The algorithm was based
upon the available data contained in the databases.
Subjects with SIRS, by definition, have two or more of the following signs or
symptoms: body temperature >38o C or <36o C, heart rate >90 bpm, respiration rate >20
breaths/min, PCO2 level <32 mm Hg, WBC >12,000 or <4,000, or bands (immature
granulocytic white blood cells) >10%. The ALF and ALI databases do not collect data for
heart rate and respiration for all seven days and does not routinely collect data on bands.
These parameters were not used to identify patients with SIRS but were used to identify
patients without SIRS.
Sepsis is defined as the presence of SIRS plus a documented infection or the
presence of at least one of the following signs or symptoms: edema or positive fluid
balance, glucose >120 mg/dL in the absence of diabetes, elevated CRP or PCT values, a
SVO2 >70%, or a cardiac index of >3.5 L/min/M2. In the case of the ALF and ALI
databases, none of the signs and symptoms data were collected on all days of the study.
Therefore, a classification of sepsis was made only when a patient had a SIRS
classification plus a confirmed infection (positive culture). Positive bacterial cultures are
considered the gold standard for infection, although this strict criterion may also miss
certain infections where a positive culture is not obtained for a variety of technical
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reasons. The presence of yeast and fungal infections was captured in the infection data
but was excluded from the analysis because a positive bacterial culture was used as the
indication of an infection. There is published evidence that yeast and fungal infections
cause an increase in SPCTC but at a lower level than those of bacterial infections
(Dornbusch et al., 2005; Martini et al., 2010; Nakamura, Wada, Takeda, & Nobori,
2009).
Severe sepsis is defined as organ failure in the presence of sepsis. Because a
diagnosis of organ failure (i.e. liver failure) has already been made by definition in the
ALF population, all ALF patients would automatically be classified as severe sepsis. For
the purposes of this study, subjects were not categorized into the severe sepsis group if
only liver failure was noted. A subject was classified into the severe sepsis category if
any additional type of organ failure other than liver failure was noted. Table 7 lists the
various biodata parameters used to denote organ failure and the type of organ failure
suggested by the parameter. The parameters acute oliguria, prolonged aPTT, and
diminished blood pressure as noted in the previous discussion, were not used as
information relevant to these parameters was not consistently collected for all days of the
study.
Septic shock is defined as the presence of severe persistent hypotension despite
adequate volume resuscitation (Levy et al., 2003) in the presence of sepsis. Because the
majority of the patients in this group were in the intensive care unit of the hospital, an
assumption of adequate fluid resuscitation was made (treatment for hypotension). A MAP
of <60 mmHg while on pressor therapy was used as an indicator of persistent
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Table 7: Severe Sepsis Signs and Symptoms
Severe Sepsis
Parameter
Arterial hypoxemia PaO2/FiO2 ratio
<300 torr
Creatinine
>0.5mg/dL increase above baseline
Coagulation abnormalities
INR >1.5
Thrombocytopenia
platelet count <100,000
Hyperbilirubinemia
total bilirubin >4 mg/dL
Hyperlactatemia
>1 mmol/L
MAP
<70 mmHg
Altered mental status
Coma Grade

Organ system
Respiratory
Kidney
Coagulation - blood
Coagulation - blood
Liver
Blood
Respiratory
Central nervous system

hypotension. Blood pressure parameters other than MAP were not utilized because
information on these parameters was not collected on all days of the studies.
Non-infected/non-SIRS ALF/ALI (Neg SIRS) samples were selected from
patients who met no more than one of the SIRS criteria. These samples were selected
from Day 1 of the study so that all parameters (WBC, pulse, respiration, temperature, and
pCO2) were available identify patients in this category. Samples with missing SIRS
criteria data were excluded.
The data were organized into a Microsoft Excel 2007 spreadsheet (Microsoft,
Redmond, WA) and condition statements (e.g., IF, AND, OR, etc.) were used to
determine the status of each ALF and ALI patient on each day of study enrollment. The
following guidelines were used to indicate a specific category:

59


Neg SIRS – if less than two of the SIRS parameters were positive



SIRS – if any two of the SIRS parameters were positive



Sepsis – presence of a confirmed bacterial infection



Severe sepsis – the presence of organ failure other than liver



Septic shock – extreme hypotension with pressor therapy

An individual subject may multiple categories during the course of the seven days of the
study however, that subject was not used for more than one category.
Because the ALF and ALI studies are non-treatment studies that were not planned
to specifically study the SIRS continuum and infection, specific data were not available
for each patient on all days of the study. Some of the biodata parameters noted in the
SIRS categories are not routinely collected by the ALF and ALI studies and the attending
physician may not have required other parameters. For the 1863 patients enrolled in the
ALF and ALI studies, there are 12,492 days of demographic and biodata information
available. However, only 3.5% of all days that all patients were enrolled in the studies
had complete data for all biodata parameters. Of those with complete biodata, only 80
days had a documented infection. The sampling plan for Specific Aim 1 described below
calls for 90 samples with a documented infection. Therefore, to maximize the availability
of samples, missing data were treated as a null value (i.e., if a lab value was missing, it
was considered to be negative for that parameter) for the purposes of categorizing the
samples. A biodata parameter had to be present and fit the criteria definition to be
considered positive.
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A power analysis was performed to determine an appropriate sample size. First,
we estimated the effects of sample size using results from the literature (GiamarellosBourboulis et al., 2002a) and log-transformed the means and standard deviations (log10)
due to the large differences in variances for each group. A sample size estimate using a
one-way ANOVA design with five levels (not infected, SIRS, sepsis, severe sepsis, and
septic shock) resulted in an effect size of 0.65, a large effect by Cohen’s standards,
(Cohen, 1977). Using this effect size estimate conservatively, a power analysis was
conducted for a factorial design with two between factors at three (etiology: APAP, viral,
and other) and 5 (infection categories) levels. Different infection groups were assumed to
have a medium effect (0.30), different etiologies were assumed to have a small effect on
the PCT values (0.15), and the interaction (etiology by infection) was assumed to have a
small effect (0.15). A minimum of 10 observations in each of the 15 cells (3 x 5) for a
total of 150 observations will achieve the following levels of power. An 83.8% power for
the comparisons of the infection groups, 35.0% power for the comparisons of the
etiologies, and 19.2% power for the interaction between etiologies and infection group
will result using an F test assuming an alpha of 0.05.
After determining the SIRS status of each ALF and ALI subject on each day of
study enrollment, samples were selected based upon the following schema described in
Table 8. The ALF/ALI project manager was given a list of possible samples for each
category. The project manager selected the appropriate number of samples from the list
of possible samples for each category based upon sample availability. If a subject was in
the same category for more than one day, only one day was used for that subject. The day
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Table 8: Categories and Numbers of Subjects Desired for Specific Aim One

Classification
Chronic/ non-ALF, not infected
Neg SIRS, not infected
SIRS, not infected
Sepsis
Sever sepsis
Septic shock
Total etiology

Etiology of Liver Disease
Viral
Other
Acetaminophen
hepatitis
Etiologies
na
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
50
60
60

Total
Classification
20
30
30
30
30
30
170

tested was the first day the subject fell into the category for which a serum sample was
available. Subjects from the Liver Disease and NSTLD databases were outpatients and
were considered to have less severe liver disease than the hospitalized ALF and ALI
subjects, negative for SIRS criteria, and classified as not infected. The chronic/nonALF/non-ALI subject category does not have an acetaminophen etiology since liver
disease caused by an overdose (either accidental or intentional) of acetaminophen is
acute, not chronic in nature.
The subjects were distributed between the different etiologies so that all types of
acute liver failure/injury were represented in the study. Etiologies were examined to
determine if they resulted in differences in SPCTC results. The SPCTC results from the
chronic group and the non-infected groups were compared to the published SPCTC
reference range for non-infected individuals (SPCTC <0.1 ng/mL) to determine if there is
a different reference range for patients with liver disease.
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Specific Aim Two
Forty-five subjects who had a positive bacterial culture identified on days four,
five, six, or seven in either ALF or ALI study were selected for SPCTC measurement. A
list of potential subjects was generated. The AFL/ALI project manager selected the
subjects based upon sample availability. Samples were obtained from the day of the
positive bacterial culture and from each of three preceding days and analyzed for SPCTC.
Specific Aim Three
Subjects who had a positive bacterial culture on Day 1 of the study were
categorized based upon their end of ALF or ALI study outcome. The subjects in this
section of the study were categorized as having either transplant free survival (TFS) or
death or liver transplant (DoT) by Day 21. If patients were placed on the liver transplant
wait list, this factor alone was not considered a bad outcome because a patient might have
improved and removed from the list. United Network for Organ Sharing (UNOS) status
one criterion is limited to ALF patients (sudden and severe onset of liver failure) and
states that a patient has a high likelihood of dying within seven days ("Questions and
answers for transplant candidates", 2008). If a patient was placed on the liver transplant
wait list and remained on the wait list through day 21, this patient was excluded from
either category. A list of subjects that fit each group was generated. The ALF/ALI
biodata manager selected 30 subjects from each group (TFS or DoT) based upon which
samples had the most available volume. One blood sample from each of the seven
sampling days each subject was enrolled in the ALF or ALI studies was requested (if
available).
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Testing
Specimen Procurement and Retrieval
A list of samples from each section of the study was given to the USALFSG
coordinator in charge of the sample repository to determine the availability of samples.
Once sample availability was confirmed, a list of the requested samples was sent to the
NIDDK. The NIDDK retrieved the requested samples and shipped them to study
personnel at Siemens Healthcare Diagnostics in Tarrytown, NY for testing. In some
cases, if a specimen was requested for more than one specific aim, the SPCTC results
from one specimen were utilized for all specific aims. Frozen samples were shipped on
dry ice using a commercial carrier. Upon receipt by study personnel at UTSW, the
samples were stored at -70o C until testing. Samples from the LDD and NSTLD sample
repositories at UTSW were also shipped on dry ice to Tarrytown, NY by commercial
courier for testing.
ADVIA Centaur Immunoassay Analyzer Testing
The ADVIA Centaur system uses a Master Curve and two-point calibration to
calibrate quantitative assays such as the PCT assay. The master curve is established as
part of the manufacturing process. Full standard curves are performed on a lot number of
PCT reagent on multiple instruments at multiple concentration levels. The RLUs at each
level is determined. The concentrations of the standards and the RLUs at each
concentration are used to generate a master curve for that lot. The PCT assay is a
sandwich assay that produces a calibration curve that has a positive slope. To minimize
instrument-to-instrument variability, reagent age, and environmental factors, a two-point
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calibration is performed when a new lot of reagent is installed on the instrument, at
specified intervals (35 days for PCT), and as needed (example: out of range control
values or major maintenance procedures). Replicates of two defined calibrators are
measured on the instrument using the assay sequence described below. If the mean RLU
values for the calibrators meet defined validity criteria, the system compares the
calibrators to the Master Curve for the lot of PCT reagent and determines a systemspecific formula for the lot of PCT reagents. The system then uses that lot/systemspecific formula to determine the PCT values of subsequently run controls and patient
samples ("Advia centaur reference manual", 2003).
The ADVIA Centaur BRAHMS PCT ("Advia centaur systems - procalcitonin
(PCT)", 2010) assay is a sandwich immunoassay composed of solid phase, lite reagent,
and ancillary reagents. The solid phase reagent contains a monoclonal mouse antibody to
fluorescein covalently linked to paramagnetic particles. The lite reagent contains a
monoclonal mouse antibody to procalcitonin that is labeled with acridinium ester. The
ancillary reagent contains a monoclonal mouse antibody to procalcitonin labeled with
fluorescein (Figure 2).

Figure 2: Siemens PCT Reagent Components
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Serum samples were thawed, mixed and placed in bar-coded sample holders and
racks that were then placed on the Centaur for analysis. The ADVIA Centaur is a random
access analyzer that can produce 270 PCT results in approximately two hours. Samples
were tested in three groups (based upon which specific aim the sample was selected for)
over the course of four days. Quality control samples (ADVIA Centaur BRAHMS PCT
quality control samples 1 and 2) were run in triplicate at the beginning and end of testing
on each day of testing. The first set of samples tested were those for Specific Aim 1. The
second and third sets of samples tested for were for Specific Aims 2 and 3, respectively.
Samples requiring a dilution, a result above the analytical range or due to low sample
volume, were tested on the fourth day using a manual dilution. Results were calculated
from the reported result by multiplying by the appropriate dilution factor.
The ADVIA Centaur system automatically processed samples to be tested for
PCT in the following sequence:
1. Combines 100 µL sample and 45 µL ancillary reagent incubates the mixture for
5.75 minutes at 370 C (Figure 3)

Figure 3: Sample + Ancillary Reagent
2. Adds 100 µL of solid phase and 50 µL of lite reagent to the mixture and incubates

for 18 minutes at 37o C (Figure 4)
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Figure 4: Add Solid Phase and Lite Reagent

.

3. Aspirates the unbound reagent, holding the solid phase in place in the reaction
cuvette by means of a magnet
4. Washes the solid phase with Wash 1 solution (a phosphate buffered saline with
sodium azide (<0.1%) and surfactant)
5. Aspirates the Wash 1 solution while holding the solid phase in the reaction
cuvette by means of a magnet.
6. Adds 300 µL of Acid Reagent to start a chemiluminescent reaction with the
acridinium ester.
7. Moves the reaction cuvette into the luminometer and adds 300 µL Base reagent
completing the chemiluminescent reaction producing a flash of light.
8. The luminometer measures the intensity of light produced by the
chemiluminescent reaction. The light is measured in relative light units (RLUs)
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The amount of RLUs detected by the system is directly proportional to the amount of
PCT present in the patient sample ("Advia centaur immunoassay system reference
manual", 2003). The measuring range is 0.02 to 75 ng/mL.
Because of regulations restricting use of reagents that have been submitted to the
FDA but have not been approved for use, testing was performed at Siemens Healthcare
Diagnostics in Tarrytown, NY. A single ADVIA Centaur was made available for use
during the four days required for testing. Siemens Healthcare Diagnostics, Tarrytown,
NY, provided all reagents required for testing.
The assigned analyzer was calibrated using a 2-point Master Curve calibration.
The master curve and calibrator values were entered into the Centaur computer system
and low and high calibrators with known values were assayed in triplicate as required for
calibration of a new lot of reagent. The average observed RLU values from the
calibrators were compared to the Master Curve and a system-specific formula was
generated. Patient and quality control samples were assayed and the observed RLU
values were adjusted using the generated system-specific formula to obtain adjusted
RLUs that were then compared to the Master Curve to obtain the final PCT
concentrations. Samples with values greater than 75 ng/mL were manually diluted using
Multi-Dil 1 ancillary reagent and the diluted samples were re-assayed as described above.
Statistical Analysis
Laboratory data from the databases were entered into Microsoft Excel 2007
spreadsheets. These data were merged with the procalcitonin data and analyzed using
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SPSS 19.0 (SPSS Inc., Chicago, IL, 2010) and SAS 9.2 (SAS Institute Inc., Cary, NC,
2008).
Descriptive statistics are included with the analysis of all sample data for all
groups. In the study, Specific Aim 1 addressed whether SPCTC (the dependent variable)
can be used to detect bacterial infections in patients with ALF and ALI. Subjects were
categorized by ALF etiology and infection with the level of infection based upon
SIRS/sepsis criteria (the independent variables). A Kruskal-Wallis test with post hoc
testing (Dunn Method) for non-parametric parameters was used to analyze the data to
determine if SPCTC can be used to detect infection, if there is a difference between
SPCTC in patients with chronic liver disease and ALF and ALI, and indicate the severity
of infection in ALF and ALI patients. The chronic group and the non-infected groups
(Neg SIRS and SIRS) means were compared to the reference range of the PCT assay. An
expected value of <0.1 ng/mL was calculated from PCT values from a population of 456
normal subjects. The 95% confidence interval for the mean concentration was 0.023 to
0.028 ng/mL ("Advia centaur and advia centaur XP systems - procalcitonin (PCT)",
2010).
A Chi-square test was used as an alternative method for analyzing the Specific
Aim 1 hypothesis. Use of chi-square required re-categorizing the samples into infection
and non-infection groups. SPCTC results were dichotomized based upon a cut-off value
indicative of infection. ROC analysis was used to determine the optimal cutoff value that
separates the specimens from the infected and non-infected subjects. The optimal cut-off
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value was defined as the point on the curve where the perpendicular distance from (and
above) the 45O line of equality is at maximum (Riffenburgh, 2006).
Specific Aim 2 addresses the use of SPCTC as a screening marker for bacterial
infection in ALF and ALI patients by determining the SPCTC (the dependent variable)
on the day of identified bacterial infection and comparing it to the SPCTC for the three
days prior to infection. The presence or absence of infection is the independent variable
for this specific aim. The day of identified infection is positive, while the previous three
days are assumed to be negative. Data pertaining to Specific Aim 2 were analyzed using a
Friedman test for non-parametric related samples to determine if SPCTC can be used as a
screening biomarker in ALF and ALI subjects who develop a bacterial infection.
Specific Aim 3 addresses the use of SPCTC to predict outcomes in ALF and ALI
patients with a bacterial infection. Subjects were categorized as having transplant free
survival or death or transplant outcomes (the independent variable). SPCTC (the
dependent variable) values for each day of the seven day study period were determined.
Data for Specific Aim 3 were analyzed using a mixed models analysis of covariance. The
following variables were explored to determine their significance in the model: visit day,
outcome (TFS or DoT), diagnosis (APAP vs. All Other Etiologies), severity of illness
(sepsis, severe sepsis, and septic shock), antibiotic therapy (prescribed or not prescribed),
antibiotic prophylaxis (prescribed or not prescribed), antibiotic use (prophylaxis and/or
therapy - prescribed or not prescribed), and coma grade (1 and 2 (mild) vs. 3 and 4
(severe)). The results of the analyses were used to determine if mean SPCTC levels were
different when accounting for features related to bacterial infection in ALF patients.

CHAPTER FOUR: RESULTS

This chapter describes the results from the statistical analysis of the data and
explores the relationship between SPCTC and severity of illness, determines if SPCTC
can detect infection, and determines if SPCTC was related to the final outcome in ALF
and ALI patients. A brief summary of statistics related to the ADVIA Centaur BRAHMS
assay will also be presented. For each specific aim, a description of how the samples
were selected will be presented along with descriptive statistics for each group of
samples. This will be followed by an overview of the results. Finally, detailed analyses
for each hypothesis will be presented. The statistical analyses and graphics prepared for
this study were performed using SPSS 19, SAS 9.2, Microsoft Excel 2007, and
SigmaPlot 12.0 (Systat Software, Inc. San Jose, CA).
Institutional Review Board (IRB) approval was obtained from the University of
Texas Southwestern Medical Center (IRB#STU092010-126) and Virginia
Commonwealth University (IRB#HM13517). Study subjects were patients who had
previously consented to enrollment into one or more of the following studies: ALF, ALI,
LDD, or NSTLD.
Assay Statistics
ADVIA Centaur BRAHMS PCT assay is sandwich immunoassay developed for
use with the ADVIA Centaur analyzer. The PCT assay was developed to aid in the
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detection and monitoring of infection and sepsis in patients suspected of having a
bacterial infection. ADVIA Centaur BRAHMS PCT low and high controls were run in
triplicate each day after the initial calibration at the beginning of the sample set (morning)
and at the end of the set (afternoon) on testing days one, two, and three. The controls
were run only in the morning on day four as the run was completed within an hour. All
control values fell within the prescribed ranges. The control values were used to calculate
within-run and between-run means, standard deviations, and coefficient of variations
(Table 9). Overall, the assay performed to the manufacturer’s specifications. However,
the CVs for this study were less than the CVs previously reported for the ADVIA
Centaur BRAHMS PCT and the KRYPTOR PCT (between-run: 3.6% to 8.6% and
within-run: 1.1% to 6.1%) (Aso, et al., 2009) .
Table 9: PCT Assay Imprecision
Control
Low (ng/mL)
High (ng/mL)

Assigned
Range
0.221 – 0.663
7.30 – 13.7

All Runs
Mean
SD
0.40
0.014
10.06
2.19

With-in Run CV BetweenLowest Highest Run CV
0.67
2.93
3.41
0.48
1.26
2.19

.
Specific Aim One
The purpose of Specific Aim 1 was to measure SPCTCs in infected and noninfected ALF and ALI patients to determine whether values observed were the same or
different from the PCT ranges based upon the severity of infection noted in previous
studies in the general population.
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Sample Selection
Data from 1863 ALF and ALI cases (1829 patients – 34 were initially enrolled in
the ALI study, subsequently developed HE, and were enrolled into the ALF study) were
entered into an Excel 2007 spreadsheet. The clinical biodata on each available day for
each subject was examined and sorted using an algorithm (see appendix A) to classify
each patient-day as representing either SIRS, sepsis, severe sepsis, or septic shock. Data
from 12,492 patient-days were sorted into the above categories. Because heart rate and
respiration were collected only on Day 1, only biodata from Day 1 were analyzed for the
Neg SIRS category. Table 10 presents the total number of patient-days identified for each
severity category. The project manager randomly selected samples for each etiology for
all severity categories based upon availability of serum samples in the sample repository.
Table 11 presents the actual number of patient-days in each category and etiology.
Table 10: Category and Sample Availability of ALF and ALI subjects
Category
Neg SIRS
(Day 1)
SIRS
(Days 1 – 7)
Sepsis
(Days 1 – 7)
Severe Sepsis
(Days 1 – 7)
Septic Shock
(Days 1 – 7)

Description
Less than 2 of SIRS values positive
2 or more SIRS values positive
SIRS with a confirmed infection and only
liver dysfunction
SIRS with a confirmed infection and
multiple organ dysfunction
SIRS with a confirmed infection and a
MAP < 60

Number Patient
Days Available
628
1407
39
(from 29 patients)
348
31
(from 25 subjects)
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Table 11: Number of Subjects Tested for PCT Based Upon Severity Category and ALF
Etiology

Classification
Chronic/ non-ALF,
not infected
Neg SIRS, not infected
SIRS
Sepsis
Sever sepsis
Septic shock
Total etiology

Etiology of Liver Disease
Viral
Other
Acetaminophen
hepatitis
Etiologies
na
10
10
10
10
6
10
5
41

10
10
1
6
1
38

10
9
6
11
10
56

Total
Classification
20
30
29
13
27
16
135

The sepsis group and the septic shock group had fewer available samples than the
other categories. There are multiple possible reasons for this. The ALF patient population
were critically ill. Samples and data were collected only once every 24 hours for the ALF
and ALI studies and the patients’ conditions could change within hours. In some cases,
samples were either not collected on a given day or the supply of aliquots had been
depleted. Single organ dysfunction (i.e., liver only) is extremely rare in this population.
The same is true of septic shock. The septic shock patients are at the most severely ill end
of the spectrum of illness. It is possible that more subjects may have actually fit into this
category, but died or underwent liver transplantation before the next day’s sample was
collected. The apparent low number of viral hepatitis subjects in three of the categories
reflects the small number of viral hepatitis cases (approximately 12%) among both ALF
and ALI registries, while APAP accounts for approximately 50%. All other etiologies
account for approximately 38%.
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Available demographic and biodata information were obtained from the LLD and
NSTLD databases for patients with chronic liver disease. In the case of the LLD
database, information was limited to demographic information. The NSTLD database did
have demographic information and biodata, but the amount of biodata was not as
extensive as the biodata collected in the ALF or ALI databases. Because the NSTLD
subjects were ambulatory (outpatients), it was assumed that the likelihood of them having
an infection was extremely small and were classified as not infected.
Demographic Information
Differences in demographic information, biodata, and laboratory values among
the severity categories were determined using one-way ANOVA for determining
differences between group means or a 2-sided Fisher’s Exact test for determining
differences between group percentages at a statistical significance level of 0.05. A
summary of the demographic information for each infection group is described in Table
12. There were significant differences in the ages (p-value = 0.030) and gender (p-value
= 0.029), but not in race (p-value = 0.479) of the subjects among the infection groups.
However, there was a higher percentage of females and caucasians than males and other
races in the study over all.
There was considerably more variation in the biodata and laboratory data among
the categories (Table 13). Pulse and respiration were significantly different between the
categories as expected since they reflect severity of illness (p-value = 0.001 for each)
while temperature and MAP were not. Note: The Septic Shock MAP was not included in
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Table 12: Demographic Data for Patients Based Upon Severity of Illness Classifications
Mean (± SD) or
Number (%)
Age (years)
Gender
Female

Chronic
n = 20

Neg
SIRS
n = 30

SIRS
n = 29

Sepsis
n = 13

Severe
Sepsis
n = 27

Septic
Shock
n = 16

53.8
(±9.4)

47.2
(±16.0)

40.5
(±15.8)

42.9
(±15.8)

40.7
(±12.5)

45.4
(±17.2)

0.030

10 (50)

15 (50)

21 (72.4)

12 (92.3)

21 (77.8)

12 (75)

0.029

5 (16.7)

5 (17.2)

2 (15.4)

3 (11.1)

1 (6.7)

p-value

Ethnicity*
Hispanic
Race*
White 14 (77.8) 21 (66.7) 23 (79.3)
9 (69.2)
24 (88.9)
14 (87.5)
0.479
African American 1 (5.6)
5 (16.7)
5 (17.2)
1 (7.7)
3 (7.7)
1 (6.2)
Asian 2 (11.1)
2 (6.7)
1 (3.4)
2 (15.4)
1 (6.2)
Hawaiian
1 (3)
Other 1 (5.6)
1 (3)
1 (7.7)
Diagnosis
APAP
10 (33.3) 10 (34.5)
6 (46.2)
10 (37.0)
5 (31.2)
Viral Hepatitis 10 (50) 10 (33.3) 10 (34.5)
6 (46.2)
6 (22.2)
1 (6.2)
Other 10 (50) 10 (33.3) 9 (31.0)
1 (7.7)
11 (40.7)
10 (62.5)
Outcome (TFS)
APAP
6 (20)
5 (17.2)
5 (38.5)
7 (25.9)
1 (6.2)
Viral Hepatitis
4 (13.3)
2 (6.9)
2 (7.4)
Other
1 (3.3)
4 (13.8)
2 (15.4)
3 (11.1)
1 (6.2)
Coma Grade
Not Reported / 0 20 (100)
4 (13.8)
1 (7.7)
2 (7.4)
1
11 (36.7)
1 (3.4)
3 (23.1)
1 (3.7)
2
11 (36.7) 8 (27.6)
1 (7.7)
3
4 (13.3)
5 (17.2)
2 (15.4)
9 (33.3)
1 (6.2)
4
4 (13.3) 11 (37.9)
6 (46.2)
15 (55.6)
15 (93.8)
Culture Types
Blood – 1
1
5
5
Tracheal – 2
6
6
4
Urine – 3
2
3
3
Wound – 4
1
2
1
Catheter – 5
1
Multiple w Blood – 7
2
8
2
Multiple wo Blood – 8
1
2
1
Antibiotics Used
19 (63.3) 23 (79.3) 11 (84.6) 22 (81.5)
13 (81.2)
0.471
Prophylaxis
15 (50) 17 (58.6)
5 (38.5)
14 (51.9)
10 (62.5)
0.718
Therapy
7 (23)
12 (41.4)
7 (53.8)
15 (55.6)
7 (43.8)
0.122
Age of Sample
8.4
6.6
6.8
7.2
6.3
6.2
0.380
(years)
(± 5.6)
(± 3.3)
(± 3.0)
(± 3.1)
(± 3.2)
(± 2.9)
After Hospital
3.9
8.6
5.8
8.2
7.2
0.002
Admission (days)
(± 2.7)
(± 10.3)
(± 3.4)
(± 5.5)
(± 6.2)
*Ethnicity: O were reported in the Chronic group; 15 of 16 were reported in the Septic Shock group
Race: 18 of 20 reported in the Chronic group / p-value reported for white vs. all other races
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Table 13: Biodata and Laboratory Values for Patients Based Upon Severity of Illness
Classifications
Chronic
Neg SIRS
SIRS
Sepsis
Severe Sepsis
Mean (± SD)
n = 20
n = 30
n = 29
n = 13
n = 27
Pulse
78 (± 18)
49 (± 56)
58 (± 63)
15 (± 38)
Respiration
16 (± 3)
11 (± 12)
11 (± 12)
3 (± 7)
Min Temperature
36.7 (± 0.8)
36.2 (± 1.5)
36.5 (± 1.3) 36.5 (± 1.1)
Max Temperature
36.8 (± 0.6)
36.6 (± 1.1)
37.2 (± 1.2) 37.7 (± 1.9)
MAP
84.4 (12.9)
84.2 (± 21.0) 92.3 (± 16.5) 88.8 (± 19.6)
Laboratory Values
WBC 5.5 (± 1.6)
8.5 (± 3.3)
13.6 (± 11.4) 15.8 (± 4.3) 15.1 (± 9.0)
Platelets 199 (± 65)
152 (± 62)
117 (± 105)
198 (± 83)
113 (± 76)
Protime
31.0 (± 14.4) 29.1 (± 15.8) 22.8 (± 9.2) 24.5 (± 11.7)
INR 0.9 (± 0.5)
3.2 (± 1.7)
2.9 (± 1.8)
2.3 (± 1.2)
2.3 (± 1.2)
Bilirubin 0.4 (± 0.2) 15.6 (± 11.0)
13.0 (± 9.9) 13.5 (± 11.0) 14.5 (± 12.0)
AST
2231 (± 4190) 1745 (± 3664) 692 (± 1278) 938 (± 1497)
ALT
2976 (± 3090) 2270 (± 4698) 1030 (± 718) 1125 (± 1532)
Creatinine 0.9 (± 0.1)
1.8 (± 1.6)
2.6 (± 2.0)
1.1 (± 0.28)
2.4 (± 1.8)
Lactate
8.6 (± 17.4)
8.8 (± 7.7)
21.0 (± 36.4)
pO2
140 (± 72)
97 (± 31)
145 (± 87)
113 (± 37)
O2 sat
98 (± 2)
93 (± 16)
96 (± 5)
98 (± 2)
pCO2
33.7 (± 4.0)
27.8 (± 7.1)
27.6 (± 1.4) 26.6 (± 6.1)
FiO2
38.6 (± 27.3) 37.8 (± 21.9) 32.4 (± 15.6) 41.5 (± 23.4)
pO2 / FiO2
422 (± 200)
277 (± 149)
456 (± 159) 270 (± 113)
*Septic Shock was not included because the MAP level is defined by the category

Septic Shock
n = 16
73 (± 60)
14 (± 13)
36.6 (± 1.4)
37.3 (± 1.2)
53.4 (± 6.6)

p
Value
0.001
0.001
0.668
0.098
0.434*

21.7 (± 19.9)
92 (± 71)
35.7 (± 23.9)
4.1 (± 2.9)
13.9 (± 9.4)
4382 (± 4390)
2145 (± 3286)
3.1 (± 1.1)
27.1 (± 40.8)
99 (± 40)
92 (± 12)
25.1 (± 5.4)
58.4 (± 33.3)
287 (± 372)

0.002
0.004
0.130
0.027
0.919
0.017
0.155
0.007
0.283
0.017
0.167
<0.001
0.065
0.399

the analysis because the MAP values were inclusion/exclusion criteria for the category.
Parameters from the laboratory data that were significantly different included WBC (pvalue = 0.002), platelet (p-value = 0.004), INR (p-value = 0.027), AST (p-value = 0.017),
creatinine (p-value = 0.007), pO2 (p-value = 0.017), and pCO2 (p-value < 0.001).
Statistical Results
Because the PCT values were not normally distributed, the PCT values were
transformed using the following equation: Log10 (PCT + 1). The horizontal line in Figure
5 represents the 2.0 ng/mL cut-off that is indicative of severe sepsis in the literature
(Harbarth et al., 2001). As can be seen, the distribution of SPCTC results of the different
severity categories vary greatly. Because the assumption of equal variances among
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Figure 5: SPCTC by SIRS Classifications
This graph represents the median transformed SPCTC values for the six patient severity groups. The
horizontal line represents the transformed 2.0 ng/mL SPCTC cutoff value indicative of severe sepsis.

groups for an ANOVA was violated, the non-parametric Kruskal-Wallis test was used to
address the following hypotheses for Specific Aim 1.
H0: There is no difference in SPCTCs between non-infected ALF/ALI patients
and non-infected chronic liver disease patients.
The Kruskal-Wallis test indicated a significant difference between the three noninfection groups (chronic, Neg SIRS, and SIRS) with a 2 = 43.682 (df = 2, p-value
<0.001). Using the post hoc multiple comparisons tests with the Dunn Method (Elliot &
Hynan, 2011), there is a significant difference between the chronic group and the Neg
SIRS (p-value <0.001) and the SIRS (p-value <0.001) groups. However, there was no
significant difference between the Neg SIRS and SIRS categories (p-value >0.05).
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The next hypothesis addressed the comparison of non-infected subjects to the
SPCTC reference value:
H0: There is no difference in SPCTSs between non-infected patients with liver
disease (chronic and ALF/ALI) and the published SPCTC reference range (<0.1
ng/mL) for non-infected patients in the general population.
For this hypothesis, a one sided t-test was used to determine if there were differences
between the SPCTC results for all non-infected patients and the documented reference
range (<0.1 ng/mL) for non-infection. When all of the non-infected patients (chronic,
Neg SIRS, and SIRS) were tested, the mean transformed SPCTC (tSPCTC) value was
0.393 (SPCTC = 1.472 ng/mL). This mean was significantly different from the null
hypothesis value of 0.1 (based upon the package insert reference range value for noninfected patients in the general population of <0.1 ng/mL) with a t value of 8.741 (df =
79, p-value <0.001). When the single outlier in the chronic patients group was removed
from the data and the analysis was repeated, the p-value was still <0.001. However, when
each category was analyzed individually, the results for patients with chronic liver
disease were not significantly different from the published reference range, while results
from each of the other two categories (Neg SIRS and SIRS) were significantly different
(Table 14).
The final Specific Aim 1 hypothesis addressed the comparison of the five severity
categories:
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Table 14: Comparison of tSPCTC in Non-Infected Patients to the Published Reference
Value (<0.1 ng/mL)
Category
All
Chronic
Neg SIRS
SIRS

Mean
(ng/mL)
0.393
0.043
0.510
0.512

SD

df

t statistic

0.357
0.017
0.327
0.358

78
19
29
28

8.741
0.511
7.854
7.089

1-sided
p-value
<0.001
0.307
<0.001
<0.001

H0: There is no difference in SPCTC between ALF/ALI patients with different
degrees of severity of infection (i.e., no infection, SIRS, sepsis, severe sepsis, and
septic shock).
Kruskal-Wallis with post hoc testing (Dunn Method) was used to evaluate the five ALF
patient categories. The Kruskal-Wallis test showed that overall there was a significant
difference in SPCTC among the five categories (2 = 15.583, df = 4, p-value = 0.003).
However, in Table 15, the mean ranks of each of the five categories indicate that the
significant differences were found only between the sepsis category and the severe sepsis
(p-value <0.01) and septic shock categories (p-value <0.05).
Table 15: Results for post hoc Pairwise Testing Using the Dunn Method
Category
No. Name
1 Neg SIRS
2 SIRS
3 Sepsis
4 Severe Sepsis
5 Septic Shock

N
30
29
13
27
16

Mean Rank
53.60
51.83
34.62
71.63
73.44

p-value

vs 2
>0.05

vs 3
>0.05
>0.05

vs 4
>0.05
>0.05
<0.01

vs 5
>0.05
>0.05
<0.05
>0.05

Subjects in the sepsis, severe sepsis, and septic shock groups were examined
based upon types of cultures: blood cultures vs. all other culture types. A 2-way analysis
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of variance was performed to examine the difference in SPCTC by type of culture (blood
vs. all other culture types), severity categories (sepsis, severe sepsis, and septic shock),
and the interaction of these two factors. The interaction between the type of culture and
severity categories (F = 0.098, dfn = 1, dfd = 50, p-value = 0.906) and the type of culture
category (F = 1.419, dfn = 1, dfd = 50, p-value = 0.239) were non-significant. However,
there was a significant difference between the severity categories (F = 3.627, dfn = 2, dfd
= 50, p-value = 0.034). While there was a difference between the transformed means for
severity, there is no difference between the SPCTC levels for subjects with positive blood
cultures and positive non-blood cultures.
Because the sepsis category did not, by definition exist in the ALF population,
SPCTC results were examined with the sepsis severity category combined with the severe
sepsis severity category. When the SPCTC results were examined without the sepsis
severity category, there were no significant differences between the categories (2 =
5.038, df = 3, p-value = 0.169).
The Neg SIRS and SIRS categories that were presumed to have no infection
demonstrated mean SPCTCs at or above the 2.0 ng/mL cut-off and while the Sepsis
category which had documented infections had a mean SPCTC that was below the 2.0
ng/mL cut-off. For this reason, there was still some uncertainty as to the actual cut-off
value denoting the presence of infection was for this population. To address this, the
SPCTC data from all categories were re-categorized based upon infection and noninfection and a ROC analysis was performed. Samples were entered into the analysis
listwise and the coordinates of the ROC curve were generated based upon sensitivity and
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1-specificity at each value for SPCTC (Figure 6). The sensitivity indicates the percentage
of samples correctly identified as infected when they are actually infected. The specificity
is the percentage of samples correctly identified as not infected when they do not have an
infection. The tests results for the ROC produced an area under the curve (AUC) equal to
0.697 (SE = 0.044, p-value <0.001). Upon examining the results of the coordinates of the
curve, it was determined that the best cut-off value for this set of data, using a
combination of criteria, was 1.62: 1) the point on the curve that was at the greatest
distance (0.186) from the 0.5 reference line at a 45O angle to the line, 2) accuracy, 3)
sensitivity (0.643), 4) specificity (0.620), and 5) likelihood ratio (1.693).

Figure 6: Receiver Operator Curve for the Detection of Infection in ALF and ALI
patients Using SPCTC
The ROC analysis resulted in an AUC of 0.697 with a sensitivity of 64.3% and a specificity of 62.0% for
the use of PCT in the detection of infection this population of ALF and ALI patients.
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When the biodata between the ALF subjects with a SPCTC, that was less than the
1.62 ng/mL cut-off and those with a SPCTC that was greater than or equal to the cut-off
are compared, with the exception of creatinine, AST, ALT, and bilirubin, all biodata
parameters had similar results (Table 16). It is uncertain how the differences in these
laboratory results impacted the SPCTC values, but they were noted. However, there are
several features of note about the > 1.62 ng/mL group. First, 52.2% of the subjects in the
> 1.62 ng/mL group had a diagnosis of acetaminophen toxicity, which was 84.5% of all
APAPs in the study. This raised a question as to whether APAP toxicity and the resulting
liver damage it caused was a factor in the increased SPCTC. In addition, the majority
(65.0%) of subjects in the Neg SIRS and SIRS categories had an outcome of death or
received a liver transplant. This will be discussed more fully later, in the discussion of
Specific Aim Three.
Fifty percent of all ALF cases in the ALFSG database are a result of APAP
toxicity. To ensure an equal distribution of etiology types in this section of the study,
equal numbers of samples were requested for each of three etiology types:
acetaminophen toxicity, viral hepatitis, and all other etiologies. An interesting trend was
noted when SPCTC results were examined based upon etiology. The SPCTC median
values for subjects with APAP toxicity were higher than the other etiologies in all of the
severity categories (Figure 7). The median SPCTC results for the severity categories with
APAP etiology were 3.0 to 6.6 times higher than the results for the respective severity
categories for all other etiologies (Table 17), again suggesting that patients with APAP
toxicity may have elevated SPCTC values unrelated to infection. However, the patterns
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Table 16: Demographic and Biodata Results Based Upon the Calculated Infection Cutoff Value of 1.62 ng/mL
SPCTCs > 1.62 ng/mL SPCTCs < 1.62 ng/mL
Mean (± SD) or
n = 67
n = 48
Number (%)
ALF Etiology
APAP
35 (52.2)
6 (12.5)
Viral hepatitis
11 (16.4)
17 (35.4)
Other
21 (31.3)
25 (52.1)

p-value

Outcome (TFS)
APAP
Viral Hepatitis
Other
WBC
Platelet
INR
Glucose
Creatinine
AST
ALT
Lactate
Bilirubin
pO2
pCO2
Pulse
Respiration
Min Temp
Max Temp
Coma Grade
0 / Not reported
1
2
3
4

21(31.3)
3 (4.5)
6 (9.0)

3 (6.2)
5 (10.4)
5 (10.4)

13.7 (+ 9.7)
120 (+ 91)
2.8 (+ 1.7)
149.0 (+ 97.7)
2.8 (+ 1.9)
2828 (+ 4142)
2870 (+ 3873)
17.4 (+ 30.2)
10.4 (+ 9.9)
111.3 (+ 41.9)
27.7 (+ 7.1)
51 (+ 49)
11 (+ 10)
36.6 (+ 1.2)
37.2 (+ 1.3)

14.4 (+ 12.9)
146 (+ 76)
3.1 (+ 2.1)
121.2 (+ 43.3)
1.4 (+ 0.8)
739 (+ 1862)
1179 (+ 1925)
7.2 (+ 7.5)
19.2 (+ 9.7)
120.3 (+ 68.5)
28.8 (+ 4.8)
68 (+ 45)
14 (+ 9)
36.5 (+ 0.9)
36.9 (+ 0.8)

4
9
9
12
33

3
7
11
9
18

Means were calculated based upon the available data

0.732
0.104
0.409
0.215
0.000
0.001
0.006
0.222
0.000
0.428
0.388
0.108
0.204
0.663
0.303
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Figure 7: Median SPCTCs by SIRS Categories Sorted by Etiologies

.

This graph represents the median transformed SPCTC values for the five patient severity groups sorted by
etiologies: APAP and All Others etiologies (combined viral and other).

Table 17: Comparison of Median SPCTC Results of Subjects in Specific Aim One Sorted
by Category and Etiologies
Neg SIRS
Median
N (ng/mL)

SIRS
Median
N (ng/mL)

Sepsis
Median
N (ng/mL)

Severe Sepsis
Median
N (ng/mL)

Septic Shock
Median
N (ng/mL)

All Etiologies

30

1.57

30

2.29

13

0.69

26

3.46

16

5.89

APAP

10

4.53

10

3.38

6

1.48

10

11.34

5

11.37

All Other Etiologies

20

1.05

20

1.07

7

0.50

16

2.41

11

1.71

of the results for the APAP and All Other Etiologies groups remain same as the overall
data: SPCTC results in the Neg SIRS and SIRS severity categories were higher than
those of the sepsis category, while the Severe Sepsis and Septic Shock categories had the
SPCTC highest levels. When Kruskal-Wallis statistical analyses were performed on the
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two etiology groups (APAP vs. all other etiologies), there were significant differences
among the severity categories for the All Other Etiologies group with a 2 = 12.942 (df =
4, p-value = 0.012). However, there were no significant differences among the severity
categories for the APAP etiology group with a 2 = 8.515 (df = 4, p-value = 0.074). The
patterns of the mean ranks for each subgroup were similar to the pattern of the mean
ranks for all subjects (Figure 8).

Figure 8: Comparison of Kruskal-Wallis Mean Ranks for All, APAP, and Other
Etiologies

,

The patterns of the mean ranks of the APAP and Other Etiologies across the five categories were similar to
the pattern for all subjects. The levels of the three etiology groupings are different due to the differing
number of subjects in each grouping.

A ROC analysis was performed on non-APAP subjects only, the AUC was 0.612
(SE = 0.066, p-value = 0.099). Upon examining the results of the coordinates of the
curve, it was determined that the best cut-off value for the non-APAP data was 1.62, with
a sensitivity of 0.543 and a specificity of 0.692.
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Specific Aim Two
The purpose of Specific Aim 2 was to determine the utility of SPCTC as a
screening biomarker for infection in ALF patients. To accomplish this, subjects with a
confirmed infection and with samples available on the day of infection and the three days
prior to the day of infection were tested to determine the SPCTC values. Results were
analyzed to determine if SPCTC results increased relative to the day of infection and on
which day – DoI, Day -1, Day -2 or Day -3.
Sample Selection
From the 1863 patients that were available from the ALF and ALI databases, 130
subjects had an infection identified on Days 4, 5, 6, or 7 without a confirmed infection on
the prior days. A list of these subjects was given to the Program Manager to randomly
select 45 subjects who had samples available for each of the four days required for this
portion of the study (DoI and 1, 2, and 3 days prior to DoI). A total of 34 subjects met
these criteria.
Demographic Information
These subjects had a mean age of 40.2 years (SD = 13.9, median = 41.0, range 18
to 73), were 61.8% female, and 88.2% Caucasian. The proportion of etiologies
represented (APAP = 44.1%, viral hepatitis = 8.8%, and all other etiologies = 47.1%)
were similar to that described by the USALFSG overall for the ALF and ALI studies
(APAP – 50%, viral hepatitis – 12%, and all other causes 38%) (Lee & Seremba, 2008;
United States Acute Liver Failure Study Group, 2011). The types of cultures that were
positive for bacterial growth were equally distributed between blood (35.3%), tracheal
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aspirates (29.4), and urine (32.3%) cultures. There was a single positive catheter culture
(2.9%). Within the blood and tracheal aspirate cultures, seven subjects had multiple
positive culture sites on the DoI (20.5% of total). Table 18 provides the demographic
information for the patients included in the analysis for Specific Aim Two.
Statistical Results
When all SPCTC values for each subject (Days -3, -2, -1, and DoI) were plotted,
the concentrations vary greatly across all days (Figure 9). There is no readily apparent
overall trend to the values. The median values for all days are in fact very similar, as can
be seen from the box plots in Figure 10. A Friedman test for non-parametric related
samples was used to test the hypothesis for this part of the study.
H0: There is no difference in SPCTC in ALF/ALI patients between the first day a
positive culture was collected and the three days prior to a positive culture.
The results of the analysis gave a 2 = 6.741 (n = 34, df = 3, p-value = 0.081) indicating
no significant difference in the PCT concentrations for the four days.
Because there appeared to be some patterns within the samples, the samples were
sorted based upon the Day -3 (D-3) and DoI serum PCT concentrations.


Subgroup A – D-3 samples were greater than the 3.0 ng/mL



Subgroup B – D-3 samples were less than 3.0 ng/mL and had an increase by DoI



Subgroup C – D-3 samples were at or below the 1.62 ng/mL cutoff and SPCTC
values remained below the 1.62 ng/mL cut-off or decreased by DoI
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Table 18: Demographic Information for 34 Patients Analyzed for SPCTC to Detect
Bacterial Infection
Mean (± SD) or Number (%)

n = 34

Gender
Female
Male

21 (61.8)
13 (38.2)

Race / Ethnicity
Hispanic
Caucasian
African-American
Asian
Native American
Age (years)
Sample age (years)
Days In Hospital Prior DoI
Etiologies
Acetaminophen
Viral Hepatitis
All others
Outcomes (TFS)
Acetaminophen
Viral Hepatitis
All others
Culture types
Blood culture -1
Tracheal aspirates - 2
Urine - 3
Catheter - 5
*Multiple w Blood – 7
**Multiple wo Blood – 8
Antibiotic
Prophylaxis
Antibiotic Therapy
Antibiotics Used
Coma Grade (DoI)
Not Reported/0
1
2
3
4

4 (11.8)
30 (88.2)
1 (2.9)
1 (2.9)
2 (5.9)
40.2 (± 13.9)
8.3 (± 2.7)
8.0 (± 5.0)
15 (44.1)
3 (8.8)
16 (47.1)
11 (32.4)
0 (0.0)
7 (20.6)
6 (17.6)
9 (26.5)
11 (32.4)
1 (2.9)
6 (17.6)
1 (2.9)
11 (32.4)
20 (58.8)
25 (73.5)
8 (23.5)
6 (17.6)
6 (17.6)
4 (11.8)
10 (29.4)

*Blood culture in combination with other culture types
** Multiple culture types in combinations that do not include blood cultures
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SPCTC [ng/mL] Log scale

100.0

SPCTC for Three Days Prior Plus DoI

10.0

1.0

0.1

D3

D2

D1

DoI

Days

Figure 9: SPCTC Results for All Subjects for Three Days Prior to and the Day of
Infection
Each series of results represents one subject’s SPCTC results for Day of Infection (DoI), one Day prior to
DoI (D-1), two Days Prior to DoI (D-2), and three Days prior to DoI (D-3).

Figure 10: SPCTC Values for DoI and Three Days Prior to DoI
The lines within the box represent the medians for the transformed SPCTC values for the Day of Infection
(DoI) and three days prior to DoI.
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The 3.0 ng/mL break between Groups A and B was chosen because it was centralized in
a nearly 1.0 ng/mL gap between the lowest Group A sample (3.48 ng/mL) and the highest
Group B sample (2.65 ng/mL) when the D-3 SPCTC values were placed in rank order.
Rank ordered D-3 SPCTC values for Groups B and C were intermixed. To help sort these
groups SPCTC values for the DOI were examined and values that increased were
assigned to Group B and those values that remained below the 1.62 ng/mL cut-off were
assigned to Group C.
In Subgroup A (Figure 11), all of the SPCTCs on D-3 were above 5.0 ng/mL with
the exception of one sample that was 3.95 ng/mL. All subjects showed a general decrease
in SPCTC by DoI.

Subgroup A

PCT [ng/mL] Log Scale

100.0

10.0

1.0

0.1

-3

-2

-1

DoI

Days

Figure 11: SPCTC Results for Subjects in Subgroup A
Subjects SPCTC results in Subgroup A were all greater than 3.0 ng/mL on D3 prior to Day of Infection.
The majority showed a decrease in the SPCTC by DoI.
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Subgroup B (Figure 12) had SPCTCs on D-3 that were <3.0 ng/mL and increased
by DoI. While the SPCTC values for some subjects initially decreased, all subjects had
SPCTC values that increase above the 3 ng/mL D-3 level on or before the DoI.

Subgroup B

PCT [ng/mL] Log Scale

100.00

10.00

1.00

0.10

-3

-2

-1

DoI

Days

Figure 12: SPCTC Results for Subjects in Subgroup B
Subjects SPCTC results in Subgroup B were all less than 3.0 ng/mL on D3 prior to Day of Infection. All
SPCTC results increased by DoI to values greater than 3 ng/mL.

Subgroup C (Figure 13) had SPCTCs on D3 that were less than or equal to the
1.62 ng/mL cutoff with the exception of one subject that had a D-3 SPCTC of 1.84
ng/mL. All subjects’ SPCTC results were less than 1.0 ng/mL by DoI.
There were no apparent differences in the demographic characteristics among
three subgroups and all subjects on the DoI with the exception of Subgroup B, which had
an increased WBC. Other variables such as lactate, pCO2, pulse, respiration, and
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Subgroup C

PCT [ng/mL] Log Scale

100.0

10.0

1.0
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Days

Figure 13: SPCTC Results for Subjects in Subgroup C
Subjects SPCTC results in Subgroup C were all less than the 1.62 ng/mL cut-off on D3 prior to Day of
Infection. The SPCTC results remained below the 1.62 ng/mL cut-off or decreased by DoI.

temperature were not calculated because in most cases there were a large number of
missing values (Table 19).
A Friedman Test was used on each of the subsets of subjects to determine if there
were any significant differences in the SPCTC results among each of the four days tested
(Table 20). The subjects from Subgroup A showed a significant change between days
with a 2 = 18.257 (df = 3, p-value <0.001). These patients had a decrease in the median
SPCTC values from 7.16 ng/dL on D-3 to 3.40 ng/dL on DoI for an overall decrease in
the mean SPCTC values of 52.5%. Using a Wilcoxon Signed Ranks test, the change
between D-3 and DoI was significant (p-value 0.013, Z = -2.480). The differences
between Day -2 (D-2) and Day -1 (D-1) and the DoI were not significant (D-2 p-values =
0.74, D-1 p-value = 0.096). While two (14.3%) of the subjects in this group did not
receive antibiotics (prophylaxis or therapy), four (28.6 %) received prophylactic
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Table 19: Demographic Data for All Subjects and Each of the Three Subgroups on the
Day of Infection
Mean (± SD) or
Number (%)

All
n = 34
Mean = 3.18
Median = 2

Subgroup A
n = 14
Mean = 4.14
Median = 2

Subgroup B
n=8
Mean = 2.13
Median = 1

Days in Hospital
Prior to D-3
Etiologies
Acetaminophen
15 (44.1)
10 (71.4%)
2 (25.0)
Viral Hepatitis
3 (8.8)
1 (12.5)
Other
16 (47.1)
4 (28.6%)
5 (62.5)
Outcome (TFS)
APAP
11 (32.4)
9 (64.3)
1 (12.5)
Viral Hepatitis
0 (0.0)
0 (0.0)
0 (0.0)
Other
7 (20.6)
3 (21.4)
2 (25.0)
WBC
13.8 (± 11.4)
12.7 (± 6.6)
20.2 (± 20.0)
Platelet
85 (± 58)
98 (± 66)
66 (± 37)
INR
2.2 (± 1.4)
1.7 (± 0.6)
1.8 (± 0.5)
Bilirubin
14.9 (± 9.8)
13.1 (± 8.1)
15.4 (± 11.7)
AST
352 (± 378)
245 (± 207)
380 (± 467)
ALT
687 (± 630)
858 (± 709)
430 (± 475)
Creatinine
2.3 (± 2.0)
2.9 (± 2.0)
3.2 (± 2.6)
Coma Grade
0 / Not reported
8 (23.5)
4 (28.6)
2 (25.0)
1
6 (17.6)
2 (14.3)
2 (25.0)
2
6 (17.6)
3 (21.4)
1 (12.5)
3
4 (11.8)
1 (7.1)
1 (12.5)
4
10 (29.4)
4 (28.6)
2 (25.0)
Antibiotics
Used
25 (73.5)
12 (85.7)
4 (50.0)
Prophylaxis
11 (32.4)
4 (28.6)
3 (37.2)
Treatment
20 (58.8)
10 (71.4)
4 (50.0)
Culture types
Blood culture -1
6 (17.6)
1 (7.1)
3 (37.5)
Tracheal aspirates - 2
9 (26.5)
4 (28.6)
3 (37.5)
Urine - 3
11 (32.4)
5 (35.7)
1 (12.5)
Catheter - 5
1 (2.9)
1 (7.1)
*Multiple w Blood – 7
6 (17.6)
3 (21.4)
1 (12.5)
**Multiple wo Blood – 8
1 (2.9)
*Blood culture in combination with other culture types
** Multiple culture types in combinations that do not include blood cultures

Subgroup C
n = 12
Mean = 2.75
Median = 2
3 (25.0)
2 (16.7)
7 (58.3)
1 (8.3)
0 (0.0)
2 (16.7)
10.6 (± 5.5)
114 (± 55)
3.0 (± 2.0)
16.9 (± 10.8)
486 (± 474)
668 (± 613)
0.9 (± 0.5)
2 (16.7)
2 (16.7)
2 (16.7)
2 (16.7)
4 (33.3)
9 (75.0)
4 (33.3)
6 (50.0)
2 (16.7)
2 (16.7)
5 (41.7)
2 (16.7)
1 (8.3)
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Table 20: Friedman Test for SPCTC Results for All Samples and Subgroups A, B, and C
Median
Mean Rank
All samples

N
34

Subset A

14

Subset B

8

Subset C

12

D-3
2.04
2.91
7.16
3.50
1.96
2.13
0.44
2.75

D-2
2.11
2.62
5.28
2.86
1.99
2.00
0.47
2.75

D-1
1.16
2.18
4.78
2.07
2.09
2.13
0.40
2.33

DoI
2.37
2.29
3.40
1.57
5.34
3.75
0.39
2.17

ChiSquare df p-value
6.741
3 0.081
18.257

3

<0.001

10.050

3

0.018

1.900

3

0.593

antibiotics and twelve (85.7 %) received antibiotics (therapy or prophylaxis). The two
subjects who did not receive antibiotics had the highest and the lowest values for all days
in this group and had documented urinary tract infections on DoI. Also of interest in this
group is the large number of APAP cases. It was noted earlier, the SPCTC results of
APAP cases appeared to have increased levels compared to the SPCTC levels for the
other etiologies. This may be influencing the results in this subgroup irrespective of any
evidence of infection.
Patients from Subgroup B also showed a significant change in the SPCTC values
between days. The median SPCTC values increased from 1.96 ng/mL on D-3, 1.99
ng/mL on D-2, 2.09 ng/mL on D-1 to 5.34 ng/mL on DoI. The Freidman test gives a
2 = 10.050 (df = 3, p-value = 0.018). The Wilcoxon Signed Ranks test showed
significant differences between DoI and both D-3 and D-2 (Z = -2.380, p-value = 0.017
and Z = -2.521, p-value = 0.012, respectively). No other pairs were significant.
Patients from Subgroup C had median SPCTC values for all days that were below
the 1.62 ng/mL cutoff. In fact there were only two values from the whole group (n = 12)
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that were at or above the cutoff on D-3 but decreased below the cutoff by D-2 and
remained there. Both patients had confirmed bacterial positive cultures on tracheal
aspirates (one also had a positive blood culture) and both received antibiotics. There were
12 subjects in C group of which 75% received antibiotics (prophylaxis or therapy). Urine
cultures accounted for 41.7% of the positive bacterial cultures followed by 33.4% blood
cultures and 25.0% tracheal aspirate cultures.
Specific Aim Three
The purpose of Specific Aim 3 was to determine if changes in the SPCTC in ALF
and ALI patients, with a confirmed bacterial infection on Day 1, would predict which of
two outcomes these patients would achieve – 1) transplant free survival or 2) death or
transplant.
Sample Selection
Of the 1863 available ALF and ALI subjects, 259 subjects had a documented
positive culture on Day 1, of which 207 had a positive culture on day 1 only. The 52
subjects with cultures on multiple days were eliminated to avoid a potentially
confounding variable. The sample list was sorted by outcome (TFS or DoT) and the list
was given to the Project Manager. Samples from 30 subjects from both outcome groups,
TFS and DoT, with serum samples for each of the seven days of the ALF or ALI studies
were requested. It was determined that there were too few subjects in either group with
all seven samples available. There are several reasons that samples might be missing that
included:
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Subjects no longer enrolled in the study due to death, transplant, discharge, or
withdrawal of consent



ALF and ALI studies are a non-treatment study that collects clinical data and
samples if available



Sample aliquot inventory from individual days may have been depleted and
therefore unavailable

The requirements were adjusted to include subjects based upon the following minimum
requirements for each subject:


Days 1 – 4 samples were available



Single days could be missing if more than 5 days were available



Missing days could not be Day 1 or any consecutive days (except at the end of the
series)

The final available sample sets were 26 subjects for the TFS group and 21 subjects for the
DoT group. Table 21 shows the number of available results for each group by day. As
can be seen, the number of available samples decreases on Days 5, 6, and 7 for both
groups but the decrease is greater in the DoT group.
Table 21: Number of Samples Tested by Days and Outcomes

TFS

N
26

DoT

21

Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Day7
26
26
25
23
22
18
16
(100%) (100%) (96.2%) (88.5%) (84.6%) (69.2%) (61.5%)
21
20
20
21
13
9
6
(100%) (95.2%) (95.2%) (100%) (61.9%) (42.9%) (28.6%)
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Demographic Information
Demographic information for both groups (TFS and DoT) is described in Table
22. Both groups were similar in all characteristics described except the etiology of ALF.
The TFS group had a higher percentage of APAP subjects (73.1%) compared to DoT
group (19.0%), while the DoT group had a higher percentage of Other etiologies (76.2%)
compared to APAP (23.1%).
A comparison of the laboratory values for TFS and DoT on DoI (see Table 23)
indicated that except for bilirubin and lactate (which are higher in the DoT group) the two
groups were similar.
Statistical Results
The SPCTC values ranged from 0.13 ng/mL to 103.75 ng/mL. Because of the
non-normally distributed SPCTC results and the large number of missing samples, a
mixed models analysis of covariance was used to test the longitudinal hypotheses. This
model has two assumptions regarding the sample data: 1) the sample results are normally
distributed and have equal variances and 2) the missing data are randomly missing.
Because the SPCTC results were widely distributed, the SPCTC values were transformed
using the following formula: Log10 (SPCTC +1) = transformed SPCTC (tSPCTC) to
address the first assumption. One was added to the SPCTC so that SPCTC results
transformed using Log10 would normalize the variances without introducing negative
numbers into the data set. Figure 14 shows the box plot representation of both categories
of tSPCTCs for all seven days. Days five, six, and seven had the largest number of
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Table 22: Demographic Information Based on Outcomes for Patients with a
Documented Infection on Day of Admission to the ALF or ALI Studies

Mean (± SD) or No. (%)

TFS (n = 26)

DoT (n = 21)

20 (76.9)
6 (23.1)

16 (76.2)
5 (23.8)

0
23 (88.5)
2 (7.7)
0
1 (3.8)
0
40.6 (± 14.5)
6.5 (± 2.9)
2.5 (± 2.0)

2 (9.5)
16 (76.2)
3 (14.3)
1 (4.8)
0
1 (4.8)
44.8 (± 13.9)
7.4 (± 2.6)
5.6 (± 10.0)

19 (73.1)
1 (3.8)
6 (23.1)

4 (19.0)
1 (4.8)
16 (76.2)

4 (15.4)
5 (19.2)
9 (34.6)
1 (3.8)
3 (11.5)
4 (15.4)

4 (19.0)
4 (19.0)
7 (33.3)
1 (4.8)
4 (19.0)
1 (4.8)

18 (69.2)
8 (30.8)
15 (57.7)

18 (85.7)
12 (57.1)
14 (66.7)

6 (23.1)
7 (26.9)
6 (23.1)
7 (26.9)

3 (14.3)
6 (28.6)
5 (23.8)
7 (33.3)

Gender
Female
Male
Race / Ethnicity
Hispanic
Caucasian
African-American
Native American
Native Hawaiian / Pacific Islander
Other
Age (years)
Sample age (years)
Days In Hospital Prior DoI
Etiologies
Acetaminophen
Viral Hepatitis
All others
Culture types
Blood culture - 1
Tracheal aspirates - 2
Urine – 3
Ascites - 6
*Multiple w Blood – 7
**Multiple wo Blood – 8
Antibiotic
Antibiotics Used
Prophylaxis
Antibiotic Therapy
Coma Grade ***
1
2
3
4

*Blood culture in combination with other culture types
** Multiple culture types in combinations that do not include blood cultures
***Based on Day 1 Coma Grade
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Table 23: Laboratory Values for Patients with a Documented Infection on the
Day of Admission to the ALF or ALI Studies
Mean (± SD)
WBC
Platelet
INR
Bilirubin
AST
ALT
Glucose
Creatinine
Lactate
pCO2
Pulse
Respiration
Min Temperature
Max Temperature

TFS (n = 26)
8.5 (± 3.8)
148 (± 95)
3.5 (± 3.4)
7.4 (± 6.6)
3718 (± 4833)
2876 (± 2821)
132 (± 50)
1.6 (± 1.3)
2.9 (± 2.0)
31 (± 7)
101 (± 30)
21 (± 7)
35.5 (± 7.3)
35.8 (± 7.4)

DoT (n = 21)
14.4 (± 15.1)
183 (± 132)
2.9 (± 1.8)
18.0 (± 11.8)
2876 (± 4657)
2392 (± 3763)
112 (± 46)
2.4 (± 1.4)
6.3 (± 4.5)
29 (± 10)
101 (± 24)
20 (± 7)
37.0 (± 0.9)
37.1 (± 1.1)

p-value
0.060
0.300
0.410
<0.001
0.549
0.616
0.183
0.058
0.017
0.367
0.964
0.623
0.373
0.420

Figure 14: Median tSPCTC per Day Sorted by Outcome
This graph represents the median transformed SPCTC results for Days 1 - 7 for the TFS (blue) and ToD
(green) outcome groups.
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missing samples (see Table 21). Six of 47 subjects had samples missing prior to their last
day in the study. All other missing samples were after Day 4. The mixed effects model
controls for Type 1 error better than other models when the missing samples rates are
different for each group, and the missing samples can be attributed to the outcome
(Mallinckrodt, Kaiser, Watkin, Molenberghs, & Carroll, 2004). In this case, the DoT
group was missing more samples than the TFS group on days five, six, and seven in large
part due to the subjects’ death or discontinuation from the study because they received a
liver transplant. The mixed model was used to test the hypotheses:
H0: There is no difference in SPCTC between ALF/ALI patients with a bacterial
infection/sepsis who have transplant free survival and those who die or receive a
liver transplant.
H0: There is no difference in changes in the serial SPCTCs between ALF/ALI
patients with a bacterial infection/sepsis who have transplant free survival and
those who die or receive a liver transplant.
There appeared to be little difference between the SPCTC results for the TFS
subjects and the DoT subjects when the transformed data was examined (Figure 14).
However, the TFS group had a larger and faster decrease in the median SPCTC results
than the DoT group. The TFS group had a decrease of 66.6% during Days 1 – 5 with an
overall decrease by Day 7 of 70.3%. The DoT group that had a 43.7% increase in the
median SPCTC values by Day 4 after which the values began falling. The overall
decrease in the median SPCTC values for the DoT group (Days 1 through 7) was 49.3%
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(Table 24). However, it should be noted that by Day 7 there were only 6 of 21 subjects
available for analysis in the DoT group compared to 16 of 26 in the TFS group.
Table 24: Change in Medians of SPCTC From Day 1 in TFS and DoT Subjects

TFS
Change per day (%)
DoT
Change per day (%)

Day 1
2.90
1.42

Day 2
2.18
24.8
1.30
8.5

Medians
Day 3 Day 4 Day 5
1.49
1.07
0.97
31.7
28.2
9.3
2.03
2.04
1.9
-56.2
-0.5
6.9

Day 6
1.12
-15.5
0.82
56.8

Day 7
0.86
23.2
0.72
12.2

To examine differences in the two outcome groups in the longitudinal
measurement of SPCTC we considered the following factors: outcome (TFS vs. DoT),
visit day, diagnosis (APAP vs. Other Etiologies), severity of illness (sepsis, severe sepsis,
and septic shock), use of antibiotics (prophylaxis and/or therapy), antibiotic prophylaxis,
antibiotic therapy, coma grade (1-2, mild vs. 3-4, severe), and interactions of these
factors. Additional analyses examined those with positive blood cultures (n = 15)
however, the number of cases was too small to adequately model the data. The final
mixed models analysis of covariance with 1-repeated measure (visit days 2, 3, 4, 5, 6, and
7), 2-between groups (outcome and antibiotic use), interaction of outcome * visit day,
and baseline SPCTC as a covariate were fit to the data. Baseline covariate of Day 1
SPCTC values was significant (p<0.0001). The interaction of outcome * visit day was
significant (p-value = 0.0403). After accounting for the baseline covariate, the least
square mean estimates for the interaction (Figure 15) show that while the values on Day 2
are similar, the tSPCTC values fell faster in the TFS group than the tSPCTC values in the
DoT group. Overall, the TFS SPCTC values were lower than the DoT SPCTC values (p-
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Figure 15: Estimates of Visit Day * Outcome by Day
This graph represents the graphical representation of the estimated least square means of Days 2 – 7 for
each of the outcome groups. Day 1 SPCT results are used as a covariate in the statistical calculation of the
means. The error bars represent the standard error for each day/outcome.

value = 0.0134) and the SPCTC values decline from Day 2 to Day 7 (p-value = 0.0011).
When comparing antibiotic use between the two groups, the TFS group had a SPCTC
mean of 0.460 ng/mL (SE + 0.027) and DoT group had a SPCTC mean of 0.591 ng/mL
(SE + 0.049). The two groups were statistically different with a p-value = 0.023.
Summary
This chapter presented the descriptive and statistical analyses for each of the study
objectives and hypotheses. Relationships between the serum procalcitonin concentrations
and the biodata variables of the ALF and ALI subjects were explored. Procalcitonin did
not appear to be a good indicator of infection as it did not adequately detect documented
infections in the ALF subjects and was elevated when there was no documented evidence

103
of infection in this study. The data showed that in the presence of infection, SPCTC
values increased as the severity of illness (determined by biodata and laboratory results).
As noted, there were numerous cases of increased SPCTC values with no documented
infection present. The SPCTC results appeared to be affected by physiologic factors
associated with various ALF etiologies, particularly APAP toxicity. Changes in SPCTC
values over time did appear to be a predictor of outcome with faster and larger decreases
in SPCTC values in subjects who survived compared to slower and smaller changes
noted for subjects who died or received a liver transplant. Interpretations of the three
specific aims will be presented in the next chapter. The interpretations will be related to
the results of the literature review.

CHAPTER FIVE: DISCUSSION

This chapter presents a review of the results presented in Chapter Four. The
results are presented in the context of the listed hypotheses, clinical implications and in
comparison to the literature review. Limitations of the study are discussed as well as
recommendations for future studies.
Overview of the Problem
Infection and sepsis is a significant problem in the general population with
mortality ranging from 10% for patients with SIRS to 50% for patients with septic shock
(Brun-Buisson, 2000; Rangel-Frausto et al., 1995). ALF patients are particularly
susceptible to infection for several reasons with a reported occurrence of 40% – 90%
(Rolando et al., 2000; Vaquero et al., 2003). ALF and ALI patients have impaired
immune function, are subject to invasive procedures, and have an increased chance of
lung infections when chest physiotherapy and bronchial suction are contraindicated due
to cerebral edema. Because of their extremely critical condition, the majority of ALF
patients spend at least a portion of their hospital stay in the ICU. Studies have shown that
admission to the ICU and use of devices (catheters, ventilators, invasive monitors, etc.)
increase the risk of acquiring an infection (Clapperton, Rolando, Sandoval, Davies, &
Williams, 1997; Rolando et al., 1990; Rolando et al., 2000; Stravitz, 2008; Suljagic et al.,
2005; Wade, Rolando, Philpott-Howard, & Wendon, 2003).
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As was noted previously, identification of infection can be difficult and is time
consuming. Therefore, finding a method that can quickly and reliably identify a bacterial
infection is of great importance. It would be an added benefit if that method could also be
used to guide antibiotic therapy. PCT has been shown in the general population to be a
reliable marker of infection and is useful as a guide for antibiotic therapy. The purpose of
this study was to determine if PCT could be utilized in the acute liver failure and acute
liver injury populations to detect infection and by utilizing SPCTC levels, improve
outcomes in this difficult situation.
Discussion of the Study
Of the 1683 patients listed in the USALFSG ALF and ALI databases, 632
subjects had an infection identified by standard bacterial culture techniques. This study
was undertaken to determine if SPCTC could be used to identify bacterial infections
sooner than standard bacterial culture in the ALF and ALI populations. Samples from
patients in the ALF and ALI databases were obtained and SPCTC concentrations were
measured to answer this question. While a study of SPCTC guided antibiotic therapy
could not be accomplished using these retrospective samples, by looking at SPCTC
results from serial samples of ALF patients based upon their outcome, this study
attempted to determined if SPCTC values for subjects who achieved TFS differed from
those who died or received a liver transplant. The study compared the differences in the
SPCTC change over time in these two groups of patients.
As can be seen in the summary of the null hypotheses in Table 25, the results of
this study were mixed.
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Table 25: Summary of Study Hypotheses
Expected
Results

Actual
Results

H : There is no difference in SPCTCs between non-infected ALF/ALI

Supported

Rejected

patients, and non-infected chronic liver disease patients.
H : There is no difference in SPCTSs between non-infected patients with

Supported

Rejected

liver disease (chronic and ALF/ALI) and the published PCT
reference range (<0.1 ng/mL) for non-infected patients in the general
population.
H : There is no difference in SPCTC between ALF/ALI patients with

Rejected

Rejected

Rejected

Supported

Specific Aim Three
H : There is no difference in SPCTC between ALF and ALI patients with

Rejected

Rejected

a bacterial infection/sepsis who have transplant free survival and
those who die or receive a liver transplant.
H : There is no difference in changes in the serial SPCTCs between

Rejected

Rejected

NULL HYPOTHESES
Specific Aim One
0

0

0

different degrees of severity of infection (i.e., Neg SIRS, SIRS,
sepsis, severe sepsis, and septic shock).

Specific Aim Two
H : There is no difference in SPCTC in ALF/ALI patients between the
0

first day a positive culture was collected and the three days prior to
the positive culture.

0

0

ALF/ALI patients with a bacterial infection/sepsis who have
transplant free survival and those who die or receive a liver
transplant.

Specific Aim One
In reviewing the data from this portion of the study, the SPCTC results varied
between the different illness severity categories. The chronic liver disease patients’
SPCTC values were at or near the expected PCT level of <0.1 ng/mL for “normal”
subjects with no infection, partially confirming the hypothesis:
H0: There is no difference in SPCTSs between non-infected patients with liver
disease (chronic and ALF/ALI) and the published PCT reference range (<0.1
ng/mL) for non-infected patients in the general population.
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While SPCTC results from cirrhotic patients in the literature (Bota,et al., 2005; Connert,
et al., 2003; Spahr, et al., 2001; Viallon et al., 2000) are mixed, the data from this study
indicate that PCT is not elevated in the presence of mild or inactive liver disease.
However, the results of ALF subjects, where the liver disease is much more severe, were
not as clear.
When looking at ALF subjects across the full SIRS spectrum (Neg SIRS, SIRS,
sepsis, sever sepsis, and septic shock) in relation to the hypotheses for this portion of the
study, there were significant differences between the severity and etiology categories.
H0: There is no difference in SPCTCs between non-infected ALF/ALI patients,
non-infected chronic liver disease patients.
H0: There is no difference in SPCTC between ALF/ALI patients with different
degrees of severity of infection (i.e., no infection, SIRS, sepsis, severe sepsis, and
septic shock).
As noted earlier in chapter four, when looking at the ALF subjects in the severity
categories with no documented infection (Neg SIRS and SIRS) in this set of samples,
there was a significant difference between both categories and the <0.1 ng/mL reference
value and the chronic patients’ levels, but no significant difference between the two
categories themselves. Thus, the milder severity of illness and presumably infection free
categories displayed at least in many instances, values that approximated those
observed in the presence of active bacterial infection. There were also significant
differences between the sepsis category and the severe sepsis and septic shock categories,
but not between Neg SIRS, SIRS, severe sepsis, and septic shock.
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Within the Neg SIRS and SIRS categories, there were 31 subjects who had
SPCTCs of 1.62 ng/mL or greater. This value was determined from the ROC analysis. Of
these subjects, 13 had indications of infection later during their hospital/study course that
could have affected the SPCTC results. These indications ranged from cultures positive
for yeast or fungus, bacterial infections one or more days after the day the tested sample
was obtained, and other evidence of infection (i.e., pancreatitis, left lower lobe infiltrate
on x-ray, tooth abscess, and VAP). Five subjects had positive bacterial cultures at some
point in the seven day course of the ALF or ALI studies after the day the PCT was
measured. It was noted earlier that there are many similarities between signs and
symptoms associated with ALF and those associated with severe sepsis. These
similarities may have resulted in a delay in identifying a bacterial infection. The possible
confounders (except yeast/fungal infections) were not captured as a variable in the
algorithm used to select samples. Therefore, they were not found until a closer
examination of the subject case report forms (CRFs) was made to determine possible
causes of the increased SPCTCs. Yeast and fungal infections are captured in the infection
data but were eliminated from the dataset as bacterial infection was use as the indication
for a positive culture. Five subjects had yeast/fungal infections during the course of the
ALF study. There is evidence that yeast and fungal infections can cause an increase in
SPCTCs, but these values on average are lower than those seen with bacterial infection
(Dornbusch et al., 2005; Martini et al., 2010; Nakamura, Wada, Takeda, & Nobori,
2009).
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The most interesting feature in this grouping of data was that the sepsis category
had a median value of 0.69 ng/mL that was significantly lower than the 1.62 ng/mL
calculated cutoff value. Surprisingly, the sepsis group levels were lower than the median
values of the Neg SIRS and SIRS categories (1.59 ng/mL and 2.29 ng/mL, respectively).
A closer examination of the subject CRFs for this category did not reveal any clear idea
as to why the results from this category with proven infections were so much lower than
the Neg SIRS and SIRS categories. There were two subjects with tracheal aspirate
cultures that were in the category with minimal evidence of infection (yeast and WBCs),
but removing them from the category does not change the median value.
All but two of the subjects in the sepsis category (84.6%) received antibiotics,
which may have been a factor in the lower SPCTC values for this category. However, all
other categories had a high percentage of antibiotics use (Neg SIRS = 63.3%, SIRS =
79.3%, Severe Sepsis = 81.5%, and Septic Shock = 81.2%) as well. There was no
difference in antibiotic use across etiologies (APAP, viral, and other) based upon the
results of the Fisher’s Exact test (p-value = 0.647). It must be noted that the timing of the
antibiotic use in relation to the time/day that the serum samples were collected was not
known. The study CRFs did not indicate when antibiotic prophylaxis or treatment was
initiated or discontinued.
When the results were examined based upon etiology, subjects with APAP
toxicity demonstrated higher SPCTC levels than those with any other etiology within
each group. Clinically, SPCTC values in subjects with APAP toxicity may not be
indicative of infection. There is evidence that APAP toxicity activates macrophages,
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resulting in the release of cytokines and proinflammatory regulators, including TNF that
contribute to APAP induced liver injury (Dragomir, J. D. Laskin, & D. L. Laskin, 2011;
Jaeschke, McGill, & Ramachandran, 2012) . While the exact origin and pathogenic
pathway of PCT is still unknown, it has been suggested that PCT is produced by
neuroendocrine cells in the liver while other data suggest that it is released by
macrophages (Matzaraki, 2007). However, there is some evidence that the increase in
PCT may be initiated by TNF and IL-1b (Whang, 1999; Domensch, 2001). The
elevated PCT may be a result of the APAP toxicity itself, but the mechanism of the sterile
inflammation remains unclear. The SPCTC levels increased as severity of disease
increased suggesting that SPCTC may still provide useful information regarding
outcomes for APAP subjects, regardless of the presence or absence of infection. If
procalcitonin is to be useful in this population, the cut-off indicating infection may need
to be set differently from the cut-offs of the general population and other ALF etiologies.
This will have to be examined in future studies.
The median values of the last two categories, severe sepsis (3.46 ng/mL) and
septic shock (5.89 ng/mL), were both well above the 1.62 ng/mL calculated cutoff and
2.0 ng/mL literature cutoff for severe sepsis (Harbarth et al., 2001). These values were
significantly different from the sepsis value of 0.69 ng/mL but not different from the Neg
SIRS and SIRS category values. In these groups, only 7 of 27 severe sepsis subjects and 3
of 16 septic shock subjects had SPCTC values less than the 1.62 ng/mL cutoff. As with
the sepsis category, there is no obvious explanation for the decreased SPCTC values in
the presence of an identified infection, except possibly the use of antibiotics. Only 5 of 27
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severe sepsis subjects and 3 of 16 septic shock subjects did not receive antibiotics. Again,
full bacterial culture reports were not available. The CRF did not contain information
related to quantity of bacterial growth or antibiotic sensitivities that might have helped
determine some of the differences among the various severity groups.
The SPCTC values of the ALF subjects when categorized by SIRS criteria appear
to be similar to those obtained in the general population noted in the literature, as can be
seen in Table 26. However, ALF Neg SIRS and SIRS values were higher than the
literature values in all but one case (Giamarellos-Bourboulis), and might be a result of the
severe liver damage, with or without bacterial infection. There have been some previous
indications in the literature that PCT values may be increased in subjects with severe liver
damage. Subjects with solid tumors that had metastasized to the liver had a higher mean
PCT value than control subjects and those with non-metastasized solid tumors (Matzaraki
et al., 2007). The sepsis and severe sepsis ALF results were similar to the literature
reports while the septic shock results were lower than all but one of the literature reports
(Brunkhorst et al., 2000; Castelli et al., 2004; E. J. Giamarellos-Bourboulis et al., 2002b;
Harbarth et al., 2001; Oberhoffer, Vogetsang, Rubwurm, Hartung, & Reinhart, 1999).
In this study when SPCTC values were compared to AST and ALT values
(indicative of the degree of liver damage) there were significant correlations. Spearman’s
rho analysis produced a correlation coefficient of 0.229 (df = 111, p-value = 0.015) for
AST and 0.192 (df = 110, p-value = 0.042) for ALT supporting the idea that SPCTC may
be increased in severe liver disease even in the absence of infection.

112
Table 26: Comparison of SPCTC Results by SIRS Category Between This Study and
Previously Published Studies
ALF

Giamarellos- Harbarth Castelli Brunkhorst Oberhoffer
Bourboulis
Mean / Median
Median
Mean
[ng/mL]
[ng/mL]
[ng/mL]
Neg SIRS /
Not Infected
SIRS
Sepsis
Severe Sepsis
Septic Shock

3.38 / 1.57
3.74 / 2.29
5.43 / 0.69
11.99 / 3.46
13.14 / 5.89

0.61
5.45
7.29
6.26
38.76

<0.2
0.6
3.5
6.2
21.3

0.14
0.38
3.0
5.58
13.1

na
0.41
0.53
6.91
12.89

na
1.3
2.0
8.7
39

Missing data, might have led to false classification of subjects. Because the
missing data were treated as negative values, subjects may have been classified in a
severity category that was lower than the severity category they might have been
classified in if all data were available.
Specific Aim Two
The purpose of this portion of the study was to determine the utility of SPCTC as
a screening biomarker for infection in ALF and ALI patients.
H0: There is no difference in SPCTC in ALF/ALI patients between the first day a
positive culture was collected and the three days prior to a positive culture.
Serial samples from 34 subjects were examined for this purpose. The selection process
for this set of samples prescribed that there was no documented infection prior to the day
of infection, which was the day of collection of a culture that resulted in growth of a
bacterial pathogen. However, when the data were examined, there was no significant
difference in SPCTC results between the four days (d-3, d-2, d-1, and DoI) with a 2 =
6.741 (n = 34, df = 3, p-value = 0.081). There were individual cases for which the
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SPCTC of the DoI increased over that of the D-3. Other cases within the category had
higher SPCTC results on D-3 than those on DoI and other cases had low SPCTC results
on D-3 that did not increase by DoI. When the subjects were sorted based upon the
SPCTC from D3 and DoI, there is some indication as to possible reasons for the results
that were obtained. The subjects were sorted based upon the following criteria:
Subgroup A samples, categorized based upon a D-3 level of > 3 ng/mL, had a
decrease in the PCT values between D3 and DoI. As discussed earlier, there are several
possible factors that may have affected the results. Subgroup A had the largest use of
antibiotics (85.7%) of all of the subgroups (B = 50.0% and C = 75.0%) and antibiotics
were more frequently used than for the whole group (73.5%). Based upon the literature
(Christ-Crain et al., 2004; Schuetz et al., 2009), this may be an indication that there were
unreported or unrecognized infections that antibiotics use were helpful in resolving.
Again, there was no documentation of negative cultures to confirm a diagnosis of no
infection and cultures were ordered at the treating physician’s discretion. Also noted, the
majority of the cases with the highest SPCTCs were from the acetaminophen toxicity
etiology. It is uncertain what the physiological process in the acetaminophen toxicity
patients is that might result in higher SPCTC results than in other ALF etiologies or if
these subjects had underlying infectious processes that went unrecognized. The later
would seem less likely because APAP subjects tend to do well. The possible link of
APAP toxicity resulting in increased SPCTC discussed earlier, seems a more likely
explanation and will have to be examined in future studies.
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Subgroup B samples were categorized based upon a D-3 SPCTC level of <3
ng/mL and increased by DoI. Overall, there was an increase in the SPCTC median values
from 1.96 ng/mL (D-3), 1.99 ng/mL (D-2), 2.09 ng/mL (D-1), to 5.34 ng/mL (DoI).
While the D-3 median SPCTC was above the 1.62 ng/mL cutoff calculated earlier, the
SPCTC increased to above the literature documented 2.0 ng/mL cutoff for severe sepsis
(Harbarth et al., 2001) by D-2. The SPCTC increased further by D-1 and DoI. This group
also had the lowest usage of antibiotics and only contained 25% APAP etiology. This
small subset of cases, counter to the other results, would support the idea that SPCTC can
be indicative of an infection even prior to DoI, similar to results seen in the general
population (Guven et al., 2002; Brunkhorst et al., 1999; Luyt et al., 2005).
Data from Subgroup C, categorized by having a D-3 result of <1.62 ng/mL, the
calculated cut-off value, and decreased or remained below the cut-off by DoI, was the
least interpretable of the subgroups. While 75.0% of this group had been prescribed
antibiotics possibly suppressing bacterial growth, their antibiotic use was not different
from antibiotic use by the whole group (73.5%). Again, there was insufficient
information concerning bacterial growth and antibiotic sensitivity and dose
administration to fully understand the results obtained. There were no other striking
features of the group with the exception, that over half of the group has ALF etiologies in
the “other” category (i.e., anything other than acetaminophen toxicity and viral hepatitis).
Again, it is unknown how much, if any, affect ALF etiology had on the SPCTC values.
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Overall, data from this group of subjects did not support the use of SPCTC as a
predictor of infection. However, it could be argued that SPCTC results for Subgroups A
and B were indicative of infection. Subgroup A may have had undetected infections at or
prior to D-3 and SPCTC predicted infections in Subgroup B at or before DoI. Future
controlled studies will be needed to better understand how useful SPCTC is in detecting
infection in ALF and ALI patients.
Specific Aim Three
The purpose of Specific Aim 3 was to determine if changes in the SPCTC of ALF
and ALI patients with a confirmed bacterial infection on day one would predict the
outcome of the patients – either TFS or DoT.
H0: There is no difference in SPCTC between ALF/ALI patients with a bacterial
infection/sepsis who have transplant free survival and those who die or receive a
liver transplant.
H0: There is no difference in the changes in the serial SPCTCs between ALF/ALI
patients with a bacterial infection/sepsis who have transplant free survival and
those who die or receive a liver transplant.
Serial samples from 47 subjects, 26 with TFS and 21 with DoT outcomes, were tested to
determine the SPCTCs. The largest difference between the two groups is that 73.1% of
the TFS group had APAP etiology while 76.2% of the DoT group had etiologies other
than APAP and viral hepatitis. This overall difference in etiologies fits with the outcomes
based upon etiology in the literature (Lee & Seremba, 2008) in which APAP etiology has
a survival rate of 58% to 64% compared to only about 20% to 25% survival for other
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etiologies including drug-induced, autoimmune, and indeterminate ALF. Use of
antibiotics was also slightly higher in the DoT group 85.7% compared to 69.2% for the
TFS group. Despite these differences, when etiology (APAP vs. Other Etiologies) was
examined as a potential covariate in the statistical model, it was not significant.
Prophylactic antibiotic use alone and antibiotic therapy alone were not significant. Coma
grade (1 – 2 vs. 3 – 4) was also examined, for significance to the model. The distribution
of coma grades between the TFS and DoT groups was similar and there was no
significance in the statistical model. While infection is associated with higher HEs, higher
HEs are also associated with lower rates of spontaneous survival (Vaquero, 2003). The
lack of difference between coma grade and the two groups may be attributed to the
differences in etiology. While both groups have similar coma grade results, APAP has a
better survival rate than other etiologies, even in the presence of higher coma grades and
infection (Vaquero, 2003).
The only other differences noted, were an increase in the bilirubin and lactate
values on DoI (Day 1) in the DoT group when compared to the TFS outcome group.
Although there were no other significant differences in other indicators of liver function
(i.e., AST, ALT, and INR), the bilirubin and lactate differences may be a function of the
differences in etiologies or the severity of the liver disease.
The composite data from this portion of the study would suggest that there was
little difference in SPCTC values between the two outcome groups. However, on closer
examination, the median SPCTC values for the TFS group (which had a large percentage
of APAP cases – 73.1%) were higher than the DoT group (76.2% etiologies other than
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APAP) median SPCTC values. Both groups demonstrated elevated median values on Day
1, TFS = 2.90 ng/mL and DoT = 1.42 ng/mL, however, the median SPCTCs for the TFS
survival group decreased faster than those for the DoT group. When the use of antibiotics
was factored into the results, the difference between the two groups was even more
apparent (see Figure 15 above). These results were similar to those reported in the
literature by others (P. E. Charles et al., 2009) when looking to use of PCT to guide
antibiotic therapy. In the PCT guided antibiotic therapy study, the decrease in SPCTCs in
patients who received appropriate antibiotic therapy was larger than the decreases seen in
patients who did not receive appropriate therapy. It cannot be determined from our data
whether appropriate antibiotic therapy was used because the ALF CRFs did not include
full microbiology reports with antibiotic sensitivities or specific information documenting
when a specific antibiotic therapy was initially given. However, when the SPCTC
profiles from the two studies are compared, the TFS group had a profile similar to the
“appropriate use of antibiotics” profile, while the DoT profile was similar to that of
subjects who received “inappropriate antibiotic therapy” (or those who did not respond to
therapy). It would appear that ALF subjects with a documented infection who have a
larger and faster decrease in SPCTC have a better outcome (i.e., TFS) than subjects
whose SPCTC do not decease as much or as rapidly (DoT group). However, further study
in which antibiotic use and etiology are controlled for will be required to confirm these
findings.
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Conclusions
Procalcitonin has proven to be useful in detecting and monitoring treatment for
infection and sepsis in the general population. While the results of this study were
hampered by factors that could not be totally controlled for or eliminated, there are some
important conclusions that can be made. High SPCTC values in ALF subjects are not
indicative of bacterial infection in many cases. While there were cases of high SPCTC
values in the presence of infection, there were some subjects who had a high SPCTC but
did not have a documented infection to justify the high SPCTC result. Further elucidation
of the relationship between increased SPCTC and severe liver disease, particularly acute
liver damage such as that resulting from APAP toxicity, is required. In addition, the
SPCTC values do appear to fall in the presence of antibiotic therapy in patients who
achieve transplant free survival but may also have simply been the result of the recovery
process itself.
What was not answered clearly is ‘What is the best cut-off value to indicate the
presence or absence of a bacterial infection in this unique patient population?’ The results
of the study were confounded by the presence of antibiotics, missing data, and small
sample sizes in some categories, despite the fact that this study utilized the largest
collection of data and samples ever amassed for this rare condition. While a cutoff of
1.62 ng/mL was calculated for the ALF/ALI population, the sensitivity (the ability of a
test to detect an infection in the presence of the infection) and specificity (the ability of a
test to not detect an infection when an infection is not present), 64.3% and 62.0%
respectively, were lower than those obtained in general population studies. When a ROC
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analysis was performed on non-APAP results, the cut-off remained the same (1.62
ng/mL), but sensitivity decreased (54.3%) and specificity increased (69.2). Whether these
changes reflect the differences in etiology or were a result of a smaller sample size, will
have to be determined by later studies. In a study by (Harbarth et al., 2001), a 97%
sensitivity and a 78% specificity were obtained at a cutoff of 1.1 ng/mL. Strong evidence
was provided that etiology affects these results. The sample size of the various etiologies
was too small for a clear determination of this effect. Further studies are needed to
discern the true utility of procalcitonin adequately in the acute liver failure population.
Infection was not readily detected in all cases. While in a small subset of subjects
infection was marked by an increased the SPCTC value on the DoI, other subjects had
increased SPCTC values up to three days (this was the maximum amount of time studied)
prior to the DoI while other subjects no elevated SPCTCs prior to or on the DoI. Again,
this is an indication that SPCTC may not be useful in this population.
The one promising aspect of this study was the fact that SPCTC values over time
were suggestive of outcome. SPCTC values that had a larger and faster decrease over
time were indicative of TFS while, slower, smaller decreases were indicative of DoT.
Limitations of the Study
The use of retrospectively collected data and samples allowed for a relatively
quick completion of this study despite the small target population, but it was also the
greatest limitation to this study. The acute liver failure databases are prospectively
collected studies designed to study acute liver failure not bacterial infection. The low
incidence of acute liver failure in the US (approximately 2500 cases per year) makes
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studying ALF challenging. The number of different etiologies confounds this even more.
In addition, only about 30% of the ALF cases (based upon the number of documented
infections in the USALFSG acute liver failure and acute liver injury databases) have a
documented infection.
While this large retrospective database allowed for quick examination of many
types of problems affecting patients with ALF, there were factors that had to be
addressed. The ALF and ALI databases contain a large amount of missing data. The
databases were prospectively collected observational studies. This means that the
database and biosample repository were compiled from available data and samples.
Unlike a clinical trial in which data and samples are collected at prescribed times, an
observational study relies on available data. ALF subjects may not have certain labs or
samples collected for a variety of reasons: labs not ordered, dis-enrolled because of liver
transplant, death, and protocol changes over the course of the 10+ years of the ALF study
changed what information was collected on the CRFs. Another reason for missing
samples was that the supply of aliquots of samples from certain time-points was depleted.
All of these factors undoubtedly affected the results of this study. Missing data
may have affected how samples were classified. The SCCM/ESICM/ACCP/ATS/SIS
International Sepsis Definitions Conference included a long list of biodata parameters
that can be used to classify patients along the SIRS continuum. While many of the ALF
and ALI parameters recorded in the CRFs of ALF and ALI subjects are among those
identified by the sepsis conference, many other parameters that could have been used
were not routinely recorded. Of those that were routinely collected, some were not
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collected on each day of the study. For this reason, subjects in the study were classified
based upon available data. This meant that subjects may have been mis-classified. An
example –a subject classified in the sepsis category should actually have been in the
severe sepsis or septic shock category because laboratory parameters that would have
changed the classification were missing. The best option would be not to use this subject,
but a review of the available data showed that of the 12,492 patient days, for the 1863
subjects of this study, available for use in this study only 3% of the all days for all
subjects had complete data. The study could not have been accomplished with only 3% of
the database available. Therefore, to maximize the sample availability, use of subjects
with missing data was allowed. In Specific Aim One, for the purpose of classifying
subjects, missing values were treated as negative values.
Missing data did not change the status of samples in the SIRS and septic shock
categories because samples in the categories were included only if specific criteria were
met. Neither a positive nor a negative value for any missing data changed the result of a
sample included in these two categories. However, missing data may have affected the
sepsis and severe sepsis categories. If a sepsis sample had missing data that had a positive
result, it could mean the sample should have been in the severe sepsis group (or severe
sepsis should have been in the septic shock group). However, it is unclear whether the
sepsis and severe sepsis groups can be clearly separated in the ALF population because
by definition all septic ALF patients should have been considered in the severe sepsis
category because of the liver failure. The attempt to separate these two groups was to
show a progression of severity. By allowing samples with missing data to be categorized,
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sample availability was maximized for categories with fewer available samples. The noninfected category was filled with subjects who are negative for SIRS and do not have a
documented infection.
Limited availability of samples in the sample repository also affected all sections
of this study. The sepsis and septic shock categories in the Specific Aim One section had
less than half of the samples requested for the study. Part of the problem with these
categories, was there were more subjects with available biodata than had available serum
samples. This was also true for Specific Aims Two and Three. Specific Aim Two was
limited to 34 subjects from a requested 45 due to limited availability of sample aliquots.
Specific Aim Three was limited to 47 subjects from a requested 60.
Missing data and samples also affected how the results were analyzed. In Specific
Aims One and Three, the analyses used were adjusted to account for missing data. In
Specific Aim One, data related to etiology were not analyzed because in the cases of the
sepsis and septic shock categories and the viral hepatitis group, there were not enough
samples to provide an adequate statistical analysis. In the case of Specific Aim Three, a
mixed methods analysis of covariance was used instead of a standard ANOVA and/or
ANCOVA. The mixed methods approach allows for the missing data without losing
degrees of freedom.
The ALF databases were not primarily designed to study infection. A prospective
study designed to examine the use of SPCTC as a biomarker of infection, would control
for antibiotic use, collect complete culture and sensitivity reports, and collect laboratory
results relevant to correct classification to the subjects. This was not the case in the ALF
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databases. While antibiotic use (both prophylaxis and therapy) was captured, dates and
times of initiation of antibiotics were not captured. Also only minimal culture
information was collected (i.e., culture type, day of the study the culture was collected,
and organisms reported). No sensitivity information relevant to the pathologic organism
was collected. Collection of cultures was based upon physician discretion and not under
set conditions. Infection was determined as present in all parts of the study only if a
positive culture was present. It was possible that an infection was present, in the
population but was not found by standard culture techniques and therefore not
documented. All of these factors affected the ability to interpret the results of this study
correctly.
Another limitation of the use of retrospective samples from the ALF repositories
was the age of the samples. There is evidence that long-term storage of samples results in
a decrease in the SPCTC results. Schuetz, et al. (2010) studied two sets of samples that
were store at -80o C for 4.8 to 5.5 years and 3.3 to 4.6 years. The SPCTCs for each set
decrease by 11.4% and 13.5% respectively. ALF samples used in this study, were stored
an average of approximately 6.75 years at -80o C storage. While it is assumed, that the
length of time in storage has decreased the SPCTCs obtained, the exact amount of
decrease is unknown and an estimate of the extent of the effect cannot be calculated. The
assumption made for this study was that the affect is equal for all samples but in reality,
this is probably not the case.
The use of the ALF databases addressed a potential threat to external validity. The
databases collect samples from subjects enrolled in the studies from medical centers
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across the US. The USALFSG has 13 active clinical sites. Prior to 2010, there were a
maximum of 23 clinical centers in the study. All of the clinical sites are major
medical/academic centers. Because smaller medical facilities are not included in this
study, this could be considered a threat to external validity. However, due to the severity
of illness presented by patients with ALF, many of these patients were transferred to
larger facilities to take advantage of a possible liver transplant (to date - the only
approved treatment for ALF other than supportive care) (Bower et al., 2007).
The one threat to external validity that has not been addressed by this study was
the use of only one PCT testing platform and only one instrument on that platform. To
date, FDA approval is limited in the US to the BRAHMS KRYPTOR and bioMérieux
Clinical Diagnostics Vidas analyzers. These platforms were not available for use in this
study. Siemens Healthcare Diagnostics has developed the ADVIA Centaur BRAHMS
PCT assay that is currently in the FDA approval for use process but has not received final
approval. The assay has been approved for use in the European Union. The ADVIA
Centaur PCT assay has shown good comparison to the KRYPTOR PCT assay. Despite
the fact that BRAHMS licenses all available assays, there is no standardization between
the assays. Due to the limited sample volume for each serum aliquot, only one result for
each sample was obtained and all samples for this study were tested on one analyzer. All
of these factors allow for potential differences in results if this study were to be repeated
on a different instrument or assay system.
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Recommendations for Future Studies
Despite the valuable information provided by this study, the best method to
answer the questions left unanswered by this study would be a controlled clinical trial of
prospectively enrolled subjects. A clinical trial with controlled conditions would diminish
or eliminate the effect of many of the problems encountered in this study. A prospective,
controlled clinical trial could:


establish minimum sample sizes for all categories (i.e., severity of illness,
etiology, outcome, etc.)



control the use of antibiotics – which antibiotics were used, documentation of
times of antibiotic initiation and discontinuation, availability of antibiotic
sensitivities for the identified bacterial organism to determine appropriateness of
prescribed antibiotics, and guidelines for antibiotic prophylaxis and therapy;



screen for the presence or absence of bacterial infections;



inclusion/exclusion criteria to provide a better categorization of subjects within
the study;



limit the amount of missing data – specific biomarkers and laboratory values
would be collected for all subjects at all specified times; and



limit missing samples – appropriate samples and sample volumes would be
collected for all subjects for all required time points.
Procalcitonin has been described as a “homokine”, a protein that has some

characteristics of a hormone and some characteristics of a cytokine. Cytokine results vary
greatly depending upon disease and immune response. This study did not have enough
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sample size to study this. Based upon the results of this study, a closer look at different
ALF etiologies in relation to SPCTC values in the presence and absence of infection may
prove useful. There was some indication in this study, that SPCTC results in subjects
with acetaminophen toxicity may be different from the SPCTC results from other
etiologies. A prospective study with a larger sample size in which determination of
infection and antibiotic use in a comparison of acetaminophen toxicity vs. non-APAP
ALF patients should be studied to adequately determine if APAP toxicity affects the
procalcitonin results.
A prospective, controlled study could potentially identify the best SPCTC cut-off
value(s) for identifying infection and sepsis in ALF patients (and if necessary specific
populations within ALF such as APAP toxicity) which could speed the identification of
bacterial infection and sepsis in this critically ill population. It could determine the utility
of antibiotic guided therapy in ALF which could shorten exposure to hepatotoxic drugs
and eliminate unnecessary prophylaxis. And, it would provide more information
regarding the relationship between PCT and severe liver disease, particularly APAP
toxicity.
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APPENDIX A

Algorithms to Determine SIRS Category for Specific Aim One Samples

Appendix A: Algorithms to determine SIRS category for Specific Aim One samples
1 = Yes

0 = No

SIRS - If column I has a value of 1, the sample is categorized as positive for SIRS.
A
Temp
<36
IF
A<36=1
otherwise =0
Sample# 0

B

C

D

E

F

pCO2
<32

G

H

I

WBC
>38
Sum Temp
>12
IF
IF
IF
A>38=1
C=1, then 1 IF E<32=1
F>12=1
otherwise =0 A + B otherwise =0 otherwise =0 otherwise =0

<4
IF
G<4=1
D+E+
otherwise =0 F+G

SIRS
IF
H>1, then 1
otherwise =0

0

0

0

0

0

0

1

1

Sepsis - If column L has a value of 1, the sample is categorized as positive for Sepsis.

Sample#

J

K

Infection

Infection
+ SIRS

L

Infection =1,
No infection =0

I+J

SEPSIS
IF
K>1, then 1
otherwise =0

1

1

1
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Severe Sepsis - If column AF has a value of 1, the sample is categorized as positive for Severe Sepsis. The group doesn’t
include patients with only liver failure in the group for septic shock. Patients with only liver failure will be
included in the sepsis category.
M

N

O

pO2/FiO2

P

Creatinine previous
Creatinine
IF
M<300=1
otherwise =0

Sample#

Sample#

281

1

>0.5

Q

R

S

Acute

Renal

Failure

ARF Adm

Dialysis

ARF
IF
P, Q, OR
R >0 =1,
otherwise =0

0

0

0

IF
O<0.5=1
otherwise =0
-0.50

0

T

U

V

W

X

INR
>1.5
IF
T>1.5=1
otherwise =0

Platelet
<100,000
IF
U<100=1
otherwise =0

Bilirubin
>4
IF
V>4=1
otherwise =0

Lactate
>1
IF
W>1=1
otherwise =0

MAP

1

0

1

0

71

Y

Z
HE / CG

<70
IF Y<70=1
otherwise
=0
0

1
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AA
with liver
components
N+S+T+U+
V+W+Y+Z

Sample#

4

AB

AC

AF

AG

IF
AA>0, then 1
otherwise =0

Severe
Sepsis
w Liver
IF
L+AB=2, =1,
otherwise =0

AD
AE
without liver
components
N+S+U+
W+Y
IF
AD>0, then 1
otherwise =0

Severe
Sepsis
wo Liver
IF
L+AE=2, =1,
otherwise =0

Compare
AC to
AF
IF
AC=AF, =1,
otherwise =0

1

1

1

1

1

1

Septic Shock - If column AK has a value of 1, the sample is categorized as positive for Septic Shock.
AH

AI

D1
MAP
<60

AJ
Pressor
therapy

IF
AH<60=1
otherwise =0
Sample#

55

1

1

AK
Septic Shock
map+prss+
sepsis
IF
L+AI+AJ=3, =1,
otherwise =0
1
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